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ABSTRACT
Substance use disorders (SUD) impact millions of women aged 15-44 in the
United States. Unintended pregnancy, which is associated with maternal and infant
morbidities, is common among women with SUD. Family planning is a leading strategy
to prevent unintended pregnancy, yet women with SUD report low rates of contraceptive
use. The goal of this research is to contribute a more nuanced understanding of how
women with SUD are provided with and use contraception during the childbearing years.
This dissertation investigates contraceptive provision and initiation trends,
patterns, and practices among reproductive-age women with and without SUD. Three
chapters make up this dissertation; each chapter is focused on a different aspect of
contraceptive care.
The first chapter describes changes in contraceptive provision between 2000-2017
for South Carolina Medicaid-enrolled women with and without SUD aged 15-44 at risk
of unintended pregnancy. Clinical performance measures for contraceptive care endorsed
by the National Quality Forum were applied to the data to assess annual percentages of
women provided most or moderately effective contraceptive methods. Contraceptive
provision of long-acting reversible methods increased more for women with SUD than
women without SUD over the study period. Provision of most or moderately effective
methods was substantially lower among women with SUD than their non-SUD
counterparts.
The second chapter compares postpartum contraceptive initiation patterns among
reproductive-age women with and without opioid use disorders (OUD) enrolled in South
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Carolina Medicaid. This study employed a counterfactual framework to balance the
distribution of covariates between women with OUD and comparison women without
OUD. Having an OUD was associated with decreased contraceptive initiation in the
postpartum period, suggesting that women with OUD face increased barriers to accessing
postpartum contraceptives than similar women without OUD.
The third chapter investigates health care providers’ self-reported contraceptive
counseling practices for their patients with SUD. Interviews were conducted with a
national sample of women’s health providers. Providers emphasized the importance of
timing contraceptive discussions appropriately, tailoring information based on patient
needs and wants, building interpersonal relationships, and prioritizing patients’
autonomy. Some providers perceived that long-acting reversible contraceptives were
most appropriate for women with SUD living with instability.
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CHAPTER ONE
INTRODUCTION
Background
Each year substance use impacts millions of reproductive-age women in the
United States (US). In 2017, 54.5% of non-pregnant and 11.5% of pregnant women aged
15-44 years reported alcohol use in the past 30 days (1). In the same year, 14.0% and
8.5% of non-pregnant and pregnant reproductive-age women, respectively, reported pastmonth illicit drug use or prescription drug misuse (1). Substance use can be defined along
a continuum from abstinence to addiction (2). Not all individuals who use alcohol or
drugs will develop problems of abuse or dependence. Substance use disorders (SUD)
diagnoses occur when repeated unhealthy patterns of substance abuse or dependence
interfere with daily life (3). According to nationally representative data, prevalence
estimates for lifetime alcohol use disorder and drug use disorder among women aged 18
and over are 22.7% (4) and 7.7% (5), respectively. These data are not available
specifically for women aged 15-44 years.
Unhealthy substance use is associated with a broad range of adverse mental and
physical health consequences, from acute conditions such as hypertension (6), insomnia
(7,8) and sudden death (9–11), to chronic illnesses such as heart disease (12,13),
depression and anxiety (14,15), and chronic liver disease (16), among others. In women
of reproductive age, substance abuse or dependence can adversely impact reproductive
health, pregnancy, and child outcomes. Notably, maternal substance use has the potential
to cause harm to the fetus when substances cross the placenta. Examples of unfavorable
pregnancy and neonatal outcomes resulting from perinatal substance use include
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spontaneous abortion, intrauterine growth restriction, preterm birth, low birth weight,
irritability, hypotonia, poor alertness or abstinence syndrome (17,18). Alcohol, which is a
widely known teratogen, may also cause birth defects, the most severe of which is fetal
alcohol syndrome (19). Longer-term effects of prenatal substance exposure on the child
can include behavioral problems, impaired cognition, or poor socioemotional or language
development (18,20).
At the population level, contraception is the most effective primary prevention
strategy for helping women to avoid unintended pregnancy, reduce abortion, achieve
healthy birth spacing, and prevent the potentially negative effects of unhealthy substance
use during pregnancy. Yet, substance-using women have suboptimal family planning
outcomes. Compared to women without SUD, women with SUD are less likely to use
contraceptives, especially highly effective methods (21,22), and almost twice as likely to
have an unplanned pregnancy. More than 75% of pregnancies among women with SUD
are unintended (23–25), compared to 45% in the general population (26). From a
population health perspective, there is an important need to develop targeted policies and
interventions to reduce unplanned pregnancies and improve contraceptive outcomes for
this population.
Trends in contraceptive provision
Advances in contraceptive technology and increased federal funding for family
planning programs since the 1960s have transformed the family planning landscape in the
US. With the increased availability and accessibility of family planning services, most
individuals in need of safe, effective contraceptive methods can access them. Evidence
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shows that nearly 100% of women who are sexually active in the US have used
contraception at some point in time (27).
While overall contraceptive prevalence in the US has remained stable for several
decades (28,29), family planning use and delivery patterns have shifted away from less
effective forms of contraception in favor of highly effective reversible methods in recent
years. In particular, intrauterine devices (IUD) and implants, or long-acting reversible
contraceptives (LARC), are growing in popularity. Between 2002-2014, the proportion of
women aged 15-44 years who used a LARC method increased from 2.4% to 14%
(29,30). Over the same period, there was a substantial decline in the proportion of women
who used less effective methods, such as diaphragm, foam, sponge, suppositories, or
jelly/cream (27–29). On the provision side, it is recommended that providers present
information about LARC before presenting information on less effective contraceptive
options (31) because these methods have low failure rates and do not require user
compliance (32).
Prior research suggests that increased LARC use or sustained improvements in
compliance with short-acting reversible contraceptives (SARC) in previous years may
have played a role in the recently declining unintended pregnancy rate in the US (26,33).
It follows that remarkably high rates of unintended pregnancy among women with SUD
may be a result of LARC underutilization or poor compliance with SARC methods in this
population. A seminal review published in 2015 by Terplan and colleagues reported that
women with SUD had a 25% lower contraceptive use prevalence than women without
SUD and that condoms accounted for a median of 62% of contraceptives used, while
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LARC or sterilization accounted for 8% of use in this population (22). Although many of
the studies reviewed by Terplan et al were conducted during years in which less effective
contraceptive methods dominated the family planning landscape, other more recent
studies have reported similar findings. A 2017 study found that having a SUD diagnosis
was associated with decreased prescription contraceptive use (21). In this and other
studies, women with SUD reported LARC use ranging from 5-12% (21,34–36).
To date, it remains unknown how contraceptive use and delivery patterns for
women with SUD have changed over time. Identifying gaps in the contraceptive services
provided to women with SUD is necessary to inform the development of family planning
programs and to improve the quality of contraceptive care delivery for this population. To
address this need, the first manuscript of this dissertation describes changes over time in
contraceptive provision for reproductive-age women with and without SUD utilizing 18
years of South Carolina (SC) Medicaid data. National Quality Forum (NQF)
contraceptive care measures were applied to the data to assess population-level rates of
provision of LARC and most or moderately effective (MME) contraceptive methods.
Percentages were stratified by SUD and by participant characteristics to assess subgroups
of women with particularly low provision patterns, indicating a need for increased access
to contraception for these groups.
Patterns in postpartum contraceptive initiation
Increased access to health insurance and health care utilization during pregnancy
and the postpartum period provide an ideal opportunity for women to access family
planning, both to reduce potential future unintended pregnancies and to optimize birth
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spacing. Despite this, there are still many women in the US who do not access
postpartum contraception and wide variation in postpartum contraceptive use exists
between states. From 2004-2006, 12% of postpartum women in 12 US states reported not
using any form of contraception and only 61.7% reported using the most effective forms
of contraception (37). Between 2003-2009, 24.4% of postpartum women in Oregon
reported using LARC while only 15.6% women in Michigan reported using these
methods (38). In a 2008 study conducted among Medicaid-enrolled, postpartum women
in California, only 41% of the women had a contraception prescription by three months
after delivery and 40% became pregnant again within 18 months (39).
Currently, there is limited research assessing postpartum contraceptive initiation
patterns among women with SUD. In three studies examining postpartum contraceptive
use in SUD populations, researchers reported varying rates of use of any method (range
25.5-50%) but fairly consistent rates of use of LARC or female sterilization (7.4-11.5%)
(25,40,41). In the only study to examine contraceptive use outcomes among women with
SUD past 90 days postpartum, 66.7% and 65.3% of study participants reported using any
contraceptives at 12 and 24 months postpartum, respectively (25). Because these studies
restricted their sample to women with opioid use disorder (OUD) or other SUD, it is still
unclear how postpartum contraceptive initiation differs among women with SUD
compared to women without SUD. Moreover, more research is needed to understand the
influence of SUD type on postpartum contraceptive outcomes, specifically how
postpartum contraceptive use compares for women with OUD and those with other
alcohol and drug disorders.
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To address these gaps, the second manuscript in this dissertation examines
patterns in postpartum initiation of MME contraceptive methods at multiple time points,
including within the immediate postpartum period and by 3, 6, and 12 months
postpartum, among women with and without OUD. Because women with OUD may be
systematically different than women without OUD, including those with non-opioid
substance use disorders (non-opioid SUD) and women without SUD, this study used
propensity score methods to adjust for baseline differences between the study groups.
The associations between OUD and postpartum contraceptive initiation were examined
using multivariable and weighted logistic regression and the predicted probabilities of
study outcomes were calculated and graphed.
Practices related to contraceptive counseling
Contraceptive counseling – the process by which patients and health care
providers consider the patients’ reproductive life goals, discuss information related to the
safety, efficacy, and side effects of a complete range of contraceptive methods, and
jointly choose a contraceptive method to help patients successfully reach their goals (42)
– is a key aspect of family planning services provision. While a variety of personal,
interpersonal and structural factors impact patients’ uptake and continued use of
contraception, contraceptive counseling may positively influence patients’ decisionmaking about method choice and initiation of chosen methods (43–45).
Data about how contraceptive counseling is performed in the US primarily come
from objective observations of contraceptive counseling interactions or from patients’ or
providers’ self-report about their counseling experiences. Few studies to date have
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collected data on contraceptive counseling through direct observation; the largest US
study to do so was the Patient-Provider Communication about Contraception (PPCC)
study. This cohort study, which recruited women aged 16-53 years seeking contraceptive
care in San Francisco area clinics between 2009 and 2012, audio-recorded a total of 342
clinical encounters (46). Multiple analyses using PPCC data show that there is wide
variation in contraceptive counseling practices, especially related to information
exchange and communication strategies, across providers in different settings as well as
within the same setting (47–51). For instance, in one analysis providers discussed side
effects of any methods at 97% of the visits (47). However, another analysis revealed that
providers told patients about hormonal side effects in only 38% of the visits in which
women selected a hormonal IUD (46).
The inconsistencies in family planning counseling and provision observed in the
PPCC study may be partly attributed to health care providers efforts to implement
patient-centered care, which involves personalizing care for each patient (52). Another
analysis with PPCC data reported that counseling was largely patient-driven, with
providers and patients engaging in a dynamic exchange of information to mutually decide
on the best contraceptive method for patients (53). This form of iterative patient-provider
communication, by which providers share their medical knowledge and patients share
their unique needs and preferences, is known as shared-decision making (SDM) (54). In
the context of family planning provision, SDM may be more effective to promote
contraceptive use than provider-driven decision-making models, which can inhibit trustbuilding (55). SDM during contraceptive provision is associated with increased overall
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patient satisfaction and satisfaction with a chosen method (56). Moreover, research shows
that SDM is consistent with women’s preferences for counseling interactions (57).
The PPCC study was conducted among women who desired contraceptive
services, so no insight can be gained from this study about when contraceptive counseling
typically happens. Prior research shows that women receive contraceptive counseling
during pregnancy and the postpartum period more often than in other time periods.
According to national survey data, approximately 80% of women have received prenatal
contraceptive counseling (58–64), and nearly 86% and 72% of women have received
postpartum counseling or counseling in both time periods, respectively (61). In contrast,
only 3%, 7%, and 29% of non-pregnant, non-postpartum women report sterilization
counseling (65,66), emergency contraception counseling (67), or any birth control
counseling (68), respectively.
There is a clear gap in the literature regarding how contraceptive counseling is
performed for women with SUD. To fill this gap, the third manuscript in this dissertation
applies qualitative methods to examine health care providers’ self-reported contraceptive
counseling practices for women with SUD. The study examines several aspects of
contraceptive counseling provision, including the context in which counseling takes
place, information shared at visits, and communication approaches, and explored
variation in reported practices based on patients’ stage of addiction recovery. This study
is important to inform clinical strategies that optimize contraceptive care for women who
use substances.
Dissertation aims
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The overarching goal of this dissertation is to examine contraceptive provision
and initiation trends, patterns, and practices among reproductive-age women with and
without SUD. This research was driven by an interest in considering upstream
approaches to reduce the potentially negative effects of prenatal substance exposure on
maternal and child health. The empirical studies that makeup this dissertation focus on
providing insights into the role of substance abuse and dependence on contraceptive
provision and use outcomes and may help inform public policy and clinical practices to
improve access to and quality of contraceptive care for women and adolescents affected
by substance abuse. The specific aims of the dissertation are:
Aim 1: To describe changes from 2000-2017 in contraceptive provision for South
Carolina Medicaid-enrolled women with and without SUD aged 15-44 at risk of
unintended pregnancy.
Aim 2: To compare postpartum contraceptive initiation patterns in South Carolina
Medicaid-enrolled women with and without OUD aged 15-44.
Aim 3: To investigate health care providers’ contraceptive counseling practices for
reproductive-age women with SUD in varying stages of addiction recovery.
Dissertation organization
This dissertation is organized into five chapters. Following this introduction, there
are three distinct studies with accompanying tables and figures at the end of the chapters
and supplementary material included in the appendices. Chapter 2 describes changes in
contraceptive provision from 2000-2017 for reproductive-age women with and without
SUD enrolled in SC Medicaid. Chapter 3 reports the postpartum contraceptive behaviors
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of women with OUD compared to women with non-opioid SUD and women without
SUD. Chapter 4 presents health care providers’ self-reported contraceptive counseling
practices for their patients with SUD. Chapter 5 summarizes each chapter, considers the
dissertation strengths and limitations, and reflects on implications for clinical and public
health practice while providing recommendations for future research.
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CHAPTER TWO
CONTRACEPTIVE PROVISION AMONG REPRODUCTIVE-AGE WOMEN WITH
AND WITHOUT SUBSTANCE USE DISORDERS: A DESCRIPTIVE STUDY OF
WOMEN ENROLLED IN SOUTH CAROLINA MEDICAID
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ABSTRACT
Objective: To describe changes in contraceptive provision between 2000-2017 for South
Carolina Medicaid-enrolled women with and without substance use disorders (SUD) aged
15-44 at risk of unintended pregnancy.
Methods: South Carolina Medicaid administrative billing data were used. We report
2000-2017 annual percentages of women provided with a: 1) most or moderately
effective (MME) contraceptive method and 2) long-acting reversible contraceptive
(LARC) method. Percentages over time were stratified on the basis of SUD type, age,
race-ethnicity, rural-urban county of residence, postpartum status, health plan type, and
benefit type.
Results: Between 2000-2017, MME provision for women with and without SUD
increased from 8.1% to 24.5% and 9.0% to 29.9%, respectively. LARC provision for
women with and without SUD increased from 0.27% to 5.27% and 0.37% 4.18%,
respectively. Compared to women without SUD, women with SUD had lower rates of
MME uptake among women aged 21-44 and higher rates of MME uptake among women
aged 15-20. Absolute rates of LARC provision were greater among women with SUD
aged 15-20 than women with or without SUD in all other age groups.
Conclusions: The percentages of South Carolina Medicaid-enrolled women with and
without SUD provided MME and LARC methods substantially increased between 20002017. Adolescent women with SUD had higher rates of contraceptive provision than
adolescent women without SUD over the study period. An opportunity for improvement
in contraceptive provision exists for South Carolina Medicaid-enrolled women of
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childbearing age who are in their later reproductive years, especially women aged 30 and
over.
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INTRODUCTION
Addressing the family planning needs of women with substance use disorders
(SUD) is an important public health priority since women with SUD report high rates of
unintended pregnancy. More than 75% of pregnancies among women with SUD are
unintended,1–4 compared with 45% in the general United States (US) population.5
Unintended pregnancies are associated with increased risk for maternal and infant
morbidities and adverse perinatal outcomes, such as low birth, postpartum depression,
and shortened duration of breastfeeding,6 and are associated with high economic costs for
society and health systems.7
Given that most unintended pregnancies occur because of contraceptive non-use
or incorrect use, several studies have sought to assess contraceptive use outcomes in
women with SUD. The existing literature states that women with SUD have lower rates
of contraceptive use and select less effective methods than their non-SUD counterparts. A
2015 review of 24 studies reported that, on average, 55% of substance-using women used
any form of contraception, compared with 81% of women who did not engage in
substance use.8 In that study, condoms were the most commonly chosen method among
women with SUD.8 A more recent study found that SUD was associated with decreased
odds of prescription contraceptive use and of choosing the most effective reversible
methods.9 What is not known, and where research is lacking, is whether contraceptive
uptake is uniformly low among women with SUD, or only low in certain subgroups in
this SUD population. Furthermore, it is unknown how contraceptive provision has
changed over time for this population.
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Limited US data are available for investigations related to contraceptive provision
in substance-using populations. Administrative claims data, which capture reimbursement
to health care providers for medical and pharmacy services received by insurance
beneficiaries, allow for such studies to be conducted. Contraceptive care measures
(CCM) can be used with claims data and have been successfully used in previous studies
to gauge trends in prescription contraceptive provision and uptake.10,11 CCM, or clinical
performance measures for contraceptive care, which were developed by the U.S. Office
of Population Affairs and Centers for Disease Control and Prevention (CDC) and
endorsed by the National Quality Forum in November 2016, are the first validated
indicators in reproductive health to measure access to and quality of contraceptive care.12
As of yet, CCM have not been adapted for use within a subpopulation, such as women
with SUD.
This study applied the NQF-endorsed CCM to South Carolina (SC) Medicaid
claims data to examine changes in contraceptive provision from 2000-2017 for women
aged 15-44 at risk of unintended pregnancy. In accordance with the CCM, we examined:
1) the percentage of women aged 15-44 years provided with a most effective
(sterilization, intrauterine devices or systems (IUD/IUD), implants) or moderately
effective (injectables, oral pills, patch, ring, or diaphragm) (MME) contraceptive method;
and, 2) the percentage of women who received only a long-acting reversible
contraceptive (IUD/IUS, implant) (LARC) method.13 Analyses were stratified on the
basis of whether or not study participants received a clinical diagnosis for SUD in the
measurement year. Given documented barriers in access to family planning services and
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contraceptive use by women with SUD, it is important to identify patterns of
contraceptive provision for this population, while also identifying subgroups of women
with particularly low contraceptive uptake whom may benefit from targeted intervention
or policy initiatives.
METHODS
Data
We examined data of SC Medicaid beneficiaries aged 15-44 years who were
enrolled in a Medicaid managed care (MMC) or fee-for-service (FFS) health plans
anytime between 2000-2017. The study years were selected to parallel the dramatic
increase in opioid use in the US. Through a data use agreement, de-identified data were
obtained from the SC Office of Research and Statistics and SC Budget and Control
Board. The data include complete medical and pharmacy claims for Medicaid
beneficiaries during the study period in addition to patient eligibility files, which contain
enrollment start and end dates and demographic information. The Clemson University
institutional review board approved this study.
Substance use disorders
We identified women with SUD on the basis of International Classification of
Diseases, 9th and 10th Revision (ICD-9 and ICD-10) diagnosis and procedure codes,
Healthcare Common Procedure Coding System (HCPCS) codes, and National Drug Code
(NDC) numbers. We defined SUD as: 1) having a primary or secondary diagnosis of
alcohol or drug abuse or dependence in >1 inpatient or emergency department claims or
>2 outpatient claims on different dates in the measurement year; or, 2) receiving
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medication for opioid or alcohol dependence in the measurement year (Appendix A).
Tobacco use was excluded from our definition of SUD as it is not reliably captured in
claims data.14
Contraceptive provision measures
Outcomes were defined as the percentage of women aged 15-44 years at risk of
unintended pregnancy who were provided with a MME method or a LARC method. As
defined in the CCM specifications, women were at risk of unintended pregnancy if they
were not pregnant, not infecund, or had a pregnancy that ended in ectopic pregnancy,
stillbirth, miscarriage, or induced abortion in the measurement year.15 Women who gave
birth in the final two months of the measurement year were excluded because postpartum
follow up, which is a common time for contraceptive initiation, was not available for
these women due to the timing of birth. Women who had a LARC method removed in the
measurement year and did not receive a subsequent LARC or MME method in that year
were excluded from the numerator. Steps and ICD-9, ICD-10, HCPCS, and NDC codes
used to calculate the CCM are listed in Appendix B.
Stratifying Variables
Stratifying variables included age (15-17, 18-20, 21-24, 25-29, 30-34, 35-39, 4044), race-ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, other racesethnicities), postpartum status during the measurement year (yes or no), county of
residence (urban or rural), health plan type (FFS or MMC) and benefit type (full
Medicaid or family planning limited benefit (FPLB)). We used the US Department of
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Agriculture’s Urban Influence Codes to identify whether beneficiaries resided in an urban
(metropolitan) or rural (nonmetropolitan) county (Appendix C).16
Statistical analysis
Women enrolled in Medicaid through the FPLB program were included in the
analysis regardless of their continuous enrollment status; for beneficiaries with full
Medicaid benefits, we excluded women with more than a 45 day gap in coverage during
the measurement year.15 We generated descriptive statistics for the sample by year. We
calculated annual unadjusted rates of MME and LARC provision for each measurement
year from 2000-2017 stratified by whether or not participants had a diagnosed SUD. We
decomposed SUD into 5 mutually exclusive types: alcohol use disorder (AUD), cannabis
use disorder (CANUD), opioid use disorder (OUD), other drug use disorder (DUD) (e.g.
cocaine, methamphetamine, hallucinogens), and polysubstance use disorder (PSUD).
Additional analyses estimated annual percentages in contraceptive provision stratified by
age, race-ethnicity, urban-rural county of residence, postpartum status, health plan type,
and benefit type.
RESULTS
Table S2.1 shows the inclusion/exclusion process for calculating the denominator
of the CCM for unadjusted analyses. After excluding women who were infecund due to
non-contraceptive reasons, who were pregnant and did not deliver in the measurement
year, or who had a pregnancy ending in November-December of the measurement year,
the final sample size of women included in the denominator ranged from 137,342 to
235,949 across study years.
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Table S2.2 reports the characteristics of the sample for each year of the study
period. Although most study participants did not have a diagnosed SUD (>97.5% across
years), the percentage of women with a SUD more than doubled over the study period,
from 1.09% in 2000 to 2.23% in 2017. The percentage of participants with an OUD
increased from 2.07% in 2000 to 22.6% in 2017. The proportion of women with an AUD
or other DUD decreased from 25.4% and 18.1% in 2000 to 9.14% and 6.50% in 2017,
respectively. On average across study years, a majority of women in the sample were
older, non-Hispanic black, never married, not pregnant in the measurement year, or
resided in urban counties. Most participants were enrolled in full Medicaid or in a FFS
plan. The number of participants enrolled in MMC increased from 0.69% in 2000 to
34.3% in 2017 while the number of women enrolled in a FPLB program decreased from
36.1% in 2000 to 18.2% in 2017.
MME Provision
Figure 2.1 shows the proportion of participants with and without SUD provided a
MME method from 2000-2017. MME provision for women with SUD increased from an
estimated 8.10% to 24.5% over this period. MME provision for women without SUD
increased from an estimated 9.00% to 29.9% in the same period. For women with SUD,
MME provision increased more than three-fold between 2000-2006, decreased
approximately 23.0% from 2006-2011, increased more than 47.0% between 2011-2013,
and decreased 15.5% from 2013-2017. The percentage of women provided a MME
method increased across all SUD types (Figure S2.1). Women with CANUD had the
greatest increase in MME provision during the study years (10.9% in 2000 to 34.5% in
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2017), while the smallest increase in MME provision was observed for women with OUD
(6.50% in 2000 to 16.4% in 2017).
MME provision increased more from 2000-2017 for women with SUD than
women without SUD among participants aged 15-20 (SUD: 5.70% to 41.2%; No SUD:
6.00% to 33.8%) and increased less during this period for women with SUD relative to
women without SUD among participants aged 21-44 (SUD: 8.80% to 21.8%; No SUD:
10.8% to 28.2%) (Figure 2.2). A deeper analysis of MME provision by age revealed that
adolescent women with SUD aged 15-17 had a greater increase in MME provision over
the study period compared to adolescent women aged 18-20 (Figure S2.2). Contraceptive
provision increased less for older adult women compared to younger adult women over
the study period for both women with and without SUD (Figures S2.3 and S2.4).
In race-stratified MME provision trends, the greatest increase in MME provision
was observed among non-Hispanic black women with SUD (7.80% in 2000 to 31.0% in
2017) followed by non-Hispanic black women without SUD (7.90% in 2000 to 30.4% in
2017) (Figure S2.5). Among non-Hispanic white participants and participants of other
racial-ethnic backgrounds, smaller increases in rates of MME provision were observed in
women with SUD than women without SUD. Across rural-urban county of residence, the
percentage of women provided a MME method increased less for women with SUD than
for women without SUD between 2000-2017 (SUD, rural: 7.80% to 25.8%; No SUD,
rural: 10.0% to 31.6%; SUD, urban: 8.20% to 24.3%; No SUD, urban: 9.50% to 27.7%)
(Figure S2.6).
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The percentage of postpartum women provided a MME method more than
doubled among women with SUD (23.6% to 52.9%) and women without SUD (25.0% to
59.4%) from 2000-2017 (Figure S2.7). Smaller increases in MME provision during this
period were observed among non-postpartum women with SUD (3.90% in 2000 to 18.5%
in 2017) relative to women without SUD (6.50% in 2000 to 27.6% in 2017). Among
women enrolled in MMC and FFS health plans, MME provision increased less from
2000-2017 for women with SUD compared to women without SUD (SUD, MMC: 6.20%
to 24.6%; No SUD, MMC: 5.00% to 30.7%; SUD, FFS: 8.20% to 24.1%; No SUD, FFS:
9.20% to 40.9%) (Figure S2.8). Overall, MME provision was generally higher for FPLB
program beneficiaries than among women enrolled in full Medicaid (Figure S2.9).
Among women enrolled in the FPLB program, the proportion of women with a diagnosed
SUD provided a MME method increased from 13.2% in 2000 to 27.1% in 2017, while
the proportion of women without SUD provided a MME method increased from 8.30% in
2000 to 33.4% to 2017.
LARC Provision
Figure 2.3 displays SUD-stratified LARC provision percentages for each year of
the study period from 2000-2017. The proportion of women with SUD provided a LARC
method increased from 0.27% in 2000 to 5.27% in 2017. The percentage of women
without a SUD provided a LARC method increased from 0.37% in 2000 to 4.18% in
2017. Between 2008-2017, LARC provision increased nearly 82.0% for women with
SUD and 27.0% for women without SUD. Though LARC provision increased across all
types of SUD from 2000-2017, participants with CANUD had the greatest increase
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(0.37% in 2000 to 8.07% in 2017), while women with OUD and other DUD had the
lowest increases over this period (OUD: 0.00% to 2.50%; other DUD: 0.37% to 2.69%)
(Figure S2.10).
Among women with SUD aged 15-20, LARC provision increased from 0.00% in
2000 to 8.49% in 2017, which was more than double the increase of LARC provision for
women without SUD aged 15-20 (0.18% in 2000 to 3.96% in 2017) (Figure 2.4). LARC
provision increased only slightly more for women with SUD than women without SUD
aged 21-44 years between 2000 and 2017 (SUD: 0.34% to 4.76%; No SUD: 0.48% to
4.28%). Among women with and without SUD aged 15-20, LARC provision increased
more over the study period for women with SUD aged 18-20 than for women without
SUD aged 18-20 and women in both groups aged 15-17 (Figure S2.11). Among adult
women, LARC provision rates were higher for younger women than older women among
women with and without SUD (Figures S2.12 and S2.13). Among adult women aged 2144, women with SUD aged 21-29 years had the greatest increase in LARC provision over
the study period.
Among all races-ethnicities, the percentage of women provided a LARC method
increased more for women with SUD than women without SUD over the study period
(Figure S2.14). The greatest increase occurred among non-Hispanic black women with
SUD (0.14% in 2000 to 6.88% in 2017), followed by non-Hispanic white women with
SUD (0.47% in 2000 to 4.83% in 2017), and then women of other races-ethnicities with
SUD (0.00% in 2000 to 4.10% in 2017). Among women residing in rural and urban
counties, LARC provision also increased more between 2000-2017 for women with SUD

28

than for women without SUD (SUD, rural: 0.30% to 4.35%; No SUD, rural: 0.35% to
3.65%; SUD, urban: 0.26% to 5.51%; No SUD, urban: 0.41% to 4.25%) (Figure S2.15).
From 2000-2017, overall LARC provision rates were significantly greater for
postpartum women than non-postpartum women (Figure S2.16). Among non-postpartum
women, LARC provision increased similarly for women with and without SUD (SUD:
0.00% in 2000 to 2.28% in 2017; No SUD: 0.48% in 2000 to 4.28% in 2017), while rates
of LARC provision increased more for postpartum women with SUD relative to
postpartum women without SUD between 2000-2017 (SUD: 1.24% to 19.5%; No SUD:
1.29% to 16.7%). Across health plan types, smaller increases in rates of LARC provision
were observed for participants enrolled in MMC than FFS plans (Figure S2.17). LARC
provision increased from 0.27% in 2000 to 7.06% in 2017 for women with SUD and
from 0.38% in 2000 to 5.19% in 2017 for women without SUD who were enrolled in FFS
Medicaid. Among FPLB and full Medicaid beneficiaries, LARC provision increased
more for women with SUD than women without SUD between 2000-2017 (SUD, FPLB:
0.00% to 5.69%; No SUD, FPLB: 0.30% to 4.45%; SUD, full Medicaid: 0.30% to 5.25%;
No SUD, full Medicaid: 0.43% to 4.05%) (Figure S2.18).
DISCUSSION
We examined SUD-stratified percentages in contraceptive provision from 20002017 among SC Medicaid-enrolled women aged 15-44 at risk of unintended pregnancy.
We found that MME provision for women with and without a diagnosed SUD more than
tripled during the 2000-2017 study period and that annual rates of MME provision in this
study were similar to those reported in other studies using the CCM.10,17 While overall
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trends for women with and without SUD were generally parallel, our data show that
women with SUD had lower absolute rates of MME contraceptive provision and uptake
than women without SUD, which is consistent with previous reports.8,9,18
The pattern of MME provision reported here did not follow trends reported in a
recent study conducted among a national sample of commercially-insured women aged
15-44. In that study, MME provision increased steadily between 2005-2013, followed by
a slight decrease in 2013.10 In contrast, MME provision in our sample increased sharply
through 2005, decreased from 2005-2012, increased again in 2013, and finally decreased
from 2013-2017. SC did not expand Medicaid under the Affordable Care Act, so the
pattern of MME provision in later years likely reflects that fact. SC Medicaid began
providing reimbursement for postpartum LARC in 2012, which would account for the
steep increase in MME provision observed in 2013. However, we have no theories to
explain why the percentage of women provided a MME method increased sharply from
2002-2005 and then decreased thereafter through 2012.
We observed that the pattern of MME provision largely did not change
differentially by SUD type over the study period. Notably, women with OUD had the
greatest decline in MME provision during later study years and the lowest absolute
percentage of MME uptake in 2017. While we observed increasing rates of CANUD,
OUD, and PSUD and decreasing rates of AUD and other DUD in this study, OUD rates
increased most rapidly during the study period, consistent with the national opioid
epidemic. Many innovative strategies have been developed and implemented to increase
access to family planning services for women with OUD. While family planning
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interventions and initiatives targeting women with OUD may be a more cost-effective use
of resources than interventions aimed at other SUD populations, it is important that all
women receive equitable access to family planning and reproductive health services.
Also of note in this study is the wide gap in MME provision observed between
women with SUD aged 15-20 years and those aged 21-44 years. Since 2003, annual
MME provision rates for women with SUD aged 15-20 were approximately double those
of women with SUD aged 21-44. In later study years, women with SUD aged 15-20 had
higher absolute rates of MME uptake than women without SUD in both age groups.
Among adolescent women, MME and LARC provision was higher among women with
SUD than women without SUD. These findings are important because they show that
MME provision for women with SUD is not lower than women without SUD during the
early reproductive years. Adolescent beneficiaries of SC Medicaid remain enrolled in the
state’s program through age 19. Accordingly, adolescents with SUD may have more
consistent access to health care as well as counseling about contraceptive methods than
adult women with SUD. As substance-using women enter adulthood, they may face extra
barriers to accessing health insurance, health care, and family planning services, which
could explain decreased rates of contraceptive provision for women with SUD aged 2144 in this study. More longitudinal investigations of contraceptive adherence and
discontinuation patterns among women with SUD are needed to identify modifiable
factors that can be targeted to facilitate contraceptive continuation for women who
discontinue using contraceptives after aging out of SC Medicaid.
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This study’s second main finding was that the percentage of women provided a
LARC method increased significantly during the study period. For all women, LARC
provision rates more than tripled between 2000-2006 and more than doubled between
2006-2008. These findings are similar to national trends in LARC use and provision,
which have increased steadily over the past two decades 19,20. However, LARC provision
rates for women without SUD in our study were lower than national estimates for
comparable study years, suggesting that LARC uptake has not increased as rapidly for SC
Medicaid beneficiaries as it has for US women of a similar age. For example, the 2014
prevalence of LARC use in the US population was 14.3% 20 compared to 4.17% for
women without SUD in our data. We observed a greater increase in LARC provision
over the study period for women with SUD relative to those without SUD. Women with
SUD also had the highest absolute rates of LARC uptake since 2013. This finding is
notable primarily because it contradicts research reporting that SUD is associated with
decreased LARC selection.9 Overall, rates of LARC uptake among women with SUD in
our study were similar to the range of 5%-12% reported across studies.2,3,8,9,21
According to the OPA, benchmarks should not be set for LARC provision
measures to discourage coercive contraceptive practices. Rather, the LARC measure
should be used to identify subgroups of women with provision below 1%-2%, indicating
that excessive barriers to LARC access exist for those groups.13 LARC provision below
2% was not detected in any stratum in this study, suggesting that there are no unnecessary
barriers that prevent SC Medicaid-enrolled, reproductive-age women from obtaining
LARC methods. SC has a longstanding and robust Medicaid family planning expansion

32

program that covers reproductive health and preventive services for low-income women
who do not qualify for full Medicaid. SC was also the first state in the US to allow
reimbursement for immediate postpartum LARC placement. Longstanding policies to
improve LARC access and availability in the state are likely responsible for generally
high LARC rates observed across all subgroups of this study in recent years.
For groups with low LARC access, research has shown that reducing financial
barriers to LARC can increase utilization. The Contraceptive CHOICE study found that
when study participants were offered their choice of any contraceptive method for free,
two-thirds of women chose LARC.22 Reimbursement policies to remove barriers to
immediate postplacental LARC insertion after childbirth have also been shown to
increase LARC uptake among women enrolled in Medicaid.11 In addition to appropriate
policies to remove financial barriers to use, potential strategies to improve access include
counseling and education about all contraceptive methods to help women make informed
choices about methods that best suit their needs and preferences, provider training to
perform insertions and removals, and primary care incentives to provide LARC to
women.
Limitations
Our study findings should be interpreted with certain limitations in mind. A
primary limitation of the CCM is correctly calculating the denominator of women at risk
of unintended pregnancy. Claims data do not contain information on sexual activity,
pregnancy seeking or pregnancy intentions, which are important considerations when
determining risk of unintended pregnancy. Moreover, because the CCM do not include a
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lookback period, the measures do not capture contraceptive use or medical procedures,
such as hysterectomy, prior to the measurement year. Based on these limitations, it is
possible that we overestimated the denominator by including women who already had a
LARC placed or underwent a contraceptive or non-contraceptive sterilization procedure
before the measurement year. If this were true, we may have underestimated the annual
percentages of women provided a MME or LARC method. Because our measurement of
contraceptive provision and uptake was based on claims data and not actual prescriptions,
it is also possible that we missed capturing some women who should have been included
in the numerator. Further, claims data may underestimate the percentage of people with a
SUD because SUD diagnoses do not appear in the data unless they are related to the
service being billed. All studies based on administrative billing records rely on the
accuracy and completeness of providers’ clinical documentation and are subject to bias.
In addition, because this research was conducted among SC Medicaid-enrolled women
aged 15-44 at risk of unintended pregnancy, findings reported here may not be
generalizable to other populations or settings. Finally, because the CCM are outcomesbased measures that do not take into consideration the process of contraceptive care
delivery, we cannot draw any conclusions about the quality of contraceptive services
provided to study participants or the factors responsible for the observed trends.
CONCLUSION
This study found that contraceptive provision and uptake increased more than
200% between 2000-2017 for reproductive-age women enrolled in SC Medicaid. MME
provision increased 232.2% for women without SUD and 202.5% for women with SUD
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during the study period. From 2012-2017, LARC provision for women with SUD
increased by 88.2%, with women with SUD having higher absolute rates of LARC
uptake after 2012 than women without SUD. Women with SUD aged 15-20 had greater
increases in MME and LARC provision over the study period than women without SUD
aged 15-20 and women with and without SUD aged 21-44. Adolescent women with
SUD also had the highest absolute rates of contraceptive uptake after 2008. Contrary to
previous research, these data suggest that women with SUD may not have lower rates of
contraceptive use than women without SUD during their adolescence and young
adulthood, but only once they transition into the later reproductive years. Further research
is needed to identify factors behind the trends and patterns observed here. Future
investigations should also examine contraceptive discontinuation patterns in adolescents
and young adult women with SUD, while identifying factors related to continuation
through later adulthood. A better understanding of facilitators to contraceptive use and
adherence through the later reproductive years for women with SUD may help substanceusing women reduce unintended pregnancies and achieve optimal reproductive health and
pregnancy outcomes.
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Figure 2.1. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder aged 15-44
at risk of unintended pregnancy provided a most or moderately effective contraceptive method, 2000-2017
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Figure 2.2. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided a
most or moderately effective contraceptive method, by age, 2000-2017
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Figure 2.3. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder aged 15-44
at risk of unintended pregnancy provided a long-acting reversible contraceptive method, 2000-2017
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Figure 2.4. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided a
long-acting reversible contraceptive method, by age, 2000-2017
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Table S2.1. Inclusion and exclusion criteria used to calculate the denominator of the contraceptive care measures for the main
analyses

Inclusion criteria for the study
Total enrollees aged 15-44 years
meeting enrollment criteria*
Exclusion criteria for
contraceptive care measures
Infecund for non-contraceptive
reasons
Still pregnant at the end of the
measurement year
Pregnancy ending in NovemberDecember of the measurement
year
Final number of women included
in the denominator

2000

2001

2002

2003

2004

2005

2006

2007

2008

139,978

155,657

176,859

176,473

173,923

177,183

168,072

148,200

147,597

365

466

716

669

570

558

539

553

540

5

6

5

3

6

8

11

7

9

2,266

2,391

2,515

2,898

2,613

2,755

2,816

2,336

2,038

137,342

152,794

173,623

172,903

170,734

173,862

164,706

145,304

145,010

*Enrollment criteria differ based on benefit type. Women with full Medicaid benefits were included in the study if they were continuously enrolled in
the measurement year (i.e. no more than a 45 day gap in enrollment). Women enrolled in the family planning limited benefit program were included
regardless of continuous enrollment.
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Table S2.1 (continued). Inclusion and exclusion criteria used to calculate the denominator of the contraceptive care measures
for the main analyses

Inclusion criteria for the study
Total enrollees aged 15-44 years
meeting enrollment criteria*
Exclusion criteria for
contraceptive care measures
Infecund for non-contraceptive
reasons
Still pregnant at the end of the
measurement year
Pregnancy ending in NovemberDecember of the measurement
year
Final number of women included
in the denominator

2009

2010

2011

2012

2013

2014

2015

2016

2017

146,707

154,853

171,736

184,216

190,421

219,578

233,843

240,786

234,902

690

726

723

634

573

748

754

848

852

8

6

8

5

5

11

170

708

486

1,941

2,020

2,090

2,268

2,239

2,606

3,176

3,281

3,267

144,068

152,101

168,915

181,309

187,504

216,213

229,743

235,949

230,297

*Enrollment criteria differ based on benefit type. Women with full Medicaid benefits were included in the study if they were continuously enrolled in
the measurement year (i.e. no more than a 45 day gap in enrollment). Women enrolled in the family planning limited benefit program were included
regardless of continuous enrollment.

43

Table S2.2. Characteristics of South Carolina Medicaid-enrolled women aged 15-44 included in the study by year, 2000-2017
Characteristics
No substance
use disorder, %
Substance use
disorder*, %
Alcohol use
disorder
Cannabis use
disorder
Opioid use
disorder
Other drug use
disorder
Polysubstance
use disorder
Age, %
15-20
21-44
Race-ethnicity,
%
Non-Hispanic
white
Non-Hispanic
black
Other raceethnicity
Rural/urban
residence, %
Rural
Urban
Postpartum, %
Yes
No
Health plan
type, %

2000
(n=137,342)

2001
(n=152,794)

2002
(n=173,623)

2003
(n=172,903)

2004
(n=170,734)

2005
(n=173,862)

2006
(n=164,706)

2007
(n=145,304)

2008
(n=145,010)

98.9

98.9

98.8

98.8

98.8

98.8

98.6

98.4

98.4

1.09

1.07

1.18

1.19

1.20

1.25

1.41

1.59

1.62

25.4

28.4

25.0

23.5

21.1

18.0

16.8

16.1

16.5

17.8

19.3

20.2

20.2

22.5

22.7

15.5

20.9

20.7

2.07

2.68

2.87

3.36

3.61

3.50

4.77

4.68

6.26

18.1

18.3

20.1

19.7

19.5

23.3

22.9

20.2

18.7

36.7

31.3

31.8

33.2

33.3

32.5

36.0

38.1

37.8

37.0
63.0

36.5
63.5

36.0
64.0

35.8
64.2

35.8
64.2

35.5
64.5

34.9
65.1

35.1
64.9

35.8
64.2

39.7

39.8

40.0

40.7

41.1

41.6

41.7

41.3

41.6

56.3

56.1

55.8

55.1

54.5

53.9

53.6

53.5

53.0

4.05

4.06

4.17

4.17

4.35

4.56

4.71

5.03

5.35

32.0
68.0

31.8
68.2

31.5
68.5

32.0
68.0

31.6
68.4

31.0
69.0

31.0
69.0

31.2
68.8

30.6
69.4

13.6
86.4

12.3
87.7

10.9
89.1

10.6
89.4

11.4
88.6

11.8
88.2

13.4
86.6

14.0
86.0

13.7
86.3
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Medicaid
managed care
Fee-for-service
Benefit type, %
Family
planning
Full Medicaid

0.69
99.3

1.41
98.6

2.39
97.6

3.30
96.7

3.04
97.0

2.76
97.2

5.01
95.0

6.07
93.9

8.71
91.3

36.1
63.9

30.8
69.2

27.2
72.8

27.4
72.6

27.6
72.4

26.8
73.2

23.0
77.0

20.5
79.5

19.3
80.7

Notes: Columns may not total 100% because of rounding.
*
Categorized into mutually exclusive groups
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Table S2.2 (continued). Characteristics of South Carolina Medicaid-enrolled women aged 15-44 included in the study by
year, 2000-2017
Characteristics
No substance
use disorder, %
Substance use
disorder*, %
Alcohol use
disorder
Cannabis use
disorder
Opioid use
disorder
Other drug use
disorder
Polysubstance
use disorder
Age, %
15-20
21-44
Race-ethnicity,
%
Non-Hispanic
white
Non-Hispanic
black
Other raceethnicity
Rural/urban
residence, %
Rural
Urban
Postpartum, %
Yes
No
Health plan

2009
(n=144,068)

2010
(n=152,101)

2011
(n=168,915)

2012
(n=181,309)

2013
(n=187,504)

2014
(n=216,213)

2015
(n=229,743)

2016
(n=235,949)

2017
(n=230,297)

98.2

97.9

98.0

98.0

98.1

97.9

97.8

97.8

97.8

1.85

2.08

2.02

1.99

1.94

2.13

2.18

2.21

2.23

14.9

14.3

14.5

13.5

12.4

9.00

8.41

8.56

9.14

20.8

20.2

19.5

19.4

18.4

16.6

17.6

21.4

21.7

6.99

10.0

12.6

12.9

12.5

11.8

14.9

21.0

22.6

14.5

12.1

10.2

10.7

8.21

4.02

4.53

6.43

6.50

42.8

43.5

43.3

43.4

48.4

58.6

54.6

42.6

40.1

36.4
63.6

35.5
64.5

33.9
66.1

33.1
66.9

34.8
65.2

33.7
66.3

32.0
68.0

30.3
69.7

29.5
70.5

42.0

42.2

42.0

42.1

41.2

41.4

40.9

40.9

40.5

52.2

51.7

51.2

51.3

51.3

50.6

50.1

48.7

48.3

5.73

6.07

6.14

6.58

7.05

7.99

9.02

8.88

9.12

30.2
69.8

23.1
76.9

22.7
67.6

22.4
77.6

22.4
77.6

21.8
78.2

21.4
78.6

21.3
78.7

21.3
78.7

12.5
87.5

11.8
88.2

11.7
88.3

11.2
88.8

10.8
89.2

10.2
89.8

9.47
90.5

8.70
91.3

8.95
91.0
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type, %
Medicaid
managed care
Fee-for-service
Benefit type, %
Family
planning
Full Medicaid

26.9
73.1

33.6
66.4

37.0
63.0

37.6
62.4

36.9
63.2

56.7
43.3

59.2
36.4

61.3
38.7

34.3
65.7

16.6
83.4

15.8
84.2

17.3
82.7

19.5
80.5

19.2
80.8

21.3
78.7

18.8
76.6

19.1
80.9

18.2
81.8

Notes: Columns may not total 100% because of rounding.
*
Categorized into mutually exclusive groups
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Figure S2.1. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a most or
moderately effective contraceptive method, by substance use disorder type, 2000-2017

Women provided a MME method, %
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Figure S2.2. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a most or
moderately effective contraceptive method, by age from 15-20, 2000-2017

Adolescent women provided a MME method, %
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Figure S2.3. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a most or
moderately effective contraceptive method, by age from 21-29, 2000-2017
Adult women aged 21-29 provided a MME method, %
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Figure S2.4. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a most or
moderately effective contraceptive method, by age from 30-44, 2000-2017

Adult women aged 30-44 provided a MME method, %
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Figure S2.5. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided
a most or moderately effective contraceptive method, by race-ethnicity, 2000-2017
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Figure S2.6. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided
a most or moderately effective contraceptive method, by rural-urban county of residence, 2000-2017
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Figure S2.7. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided
a most or moderately effective contraceptive method, by postpartum status, 2000-2017
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Women provided a MME method, %

Figure S2.8. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided
a most or moderately effective contraceptive method, by health plan type, 2000-2017
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Figure S2.9. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided
a most or moderately effective contraceptive method, by benefit type, 2000-2017
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Figure S2.10. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a longacting reversible contraceptive method, by substance use disorder type, 2000-2017

Alcohol use diorder
Cannabis use disorder

Women provided a LARC method, %

9

Opioid use disorder
Other drug use disorder
Polysubstance use disorder

6

3

0
2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

Substance use disorder stratified by type, %
Alcohol use disorder

0.26

0.00

0.00

0.00

0.69

0.26

0.26

1.08

2.33

1.77

2.88

2.02

1.64

4.19

3.38

4.99

1.34

5.32

Cannabis use disorder

0.37

0.32

0.48

1.44

1.30

0.41

1.76

1.45

4.53

3.43

4.08

3.60

4.86

6.56

8.13

10.90

7.34

8.07

Opioid use disorder

0.00

0.00

0.00

0.00

1.35

1.32

0.90

0.93

2.04

1.61

1.58

3.48

2.37

2.63

2.57

2.55

2.65

2.50

Other drug use disorder

0.37

0.00

0.24

0.74

0.50

0.39

0.94

1.29

2.27

3.10

4.46

2.02

1.04

3.01

5.41

3.52

5.06

2.69

Polysubstance use disorder

0.18

0.19

0.00

0.59

1.03

0.85

1.07

1.14

2.70

3.08

2.40

2.77

2.82

3.74

3.71

4.98

4.13

5.73

57

Adolescent women provided a LARC method, %

Figure S2.11. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a longacting reversible contraceptive method, by age from 15-20, 2000-2017
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Figure S2.12. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a longacting reversible contraceptive method, by age from 21-29, 2000-2017
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Figure S2.13. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a longacting reversible contraceptive method, by age from 30-44, 2000-2017
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Figure S2.14. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided
a long-acting reversible contraceptive method, by race-ethnicity, 2000-2017
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Figure S2.15. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided
a long-acting reversible contraceptive method, by rural-urban county of residence, 2000-2017
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Figure S2.16. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided
a long-acting reversible contraceptive method, by postpartum status, 2000-2017
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Figure S2.17. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided
a long-acting reversible contraceptive method, by health plan type, 2000-2017
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Figure S2.18. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided
a long-acting reversible contraceptive method, by benefit type, 2000-2017
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CHAPTER THREE
PATTERNS IN POSTPARTUM CONTRACEPTIVE INITIATION AMONG
REPRODUCTIVE-AGE WOMEN WITH AND WITHOUT OPIOID USE DISORDERS:
EVIDENCE FROM SOUTH CAROLINA MEDICAID CLAIMS
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ABSTRACT
Background: Non-postpartum women with opioid use disorder (OUD) and other substance use
disorders (SUD) report a lower prevalence of contraceptive use than non-substance-using
women. Limited research has examined whether this extends to women in the postpartum period.
Moreover, no studies have assessed differences in the postpartum contraception behaviors of
women with OUD and women with non-opioid SUD.
Objective: To investigate patterns in postpartum contraceptive initiation among women with
OUD, women with non-opioid SUD, and women without SUD.
Methods: This retrospective cohort study included South Carolina Medicaid-enrolled
women aged 15-44 who had singleton live birth between January 2005 to June 2017. We
identified the study sample and variables using common diagnostic, procedural, and drug code
sets. We used multivariable logistic regression and inverse probability of treatment weighting
analyses to estimate the relationship between OUD and contraceptive initiation in the immediate
postpartum period and at 3, 6, and 12 months postpartum.
Results: There were 23,326 live birth deliveries from 2005 to mid-2017. The total number of
women with a SUD was 1,622, including 244 women with an OUD and 1,378 women with a
non-opioid SUD. The prevalence of postpartum contraceptive initiation at 12 months after
delivery was lower for women with OUD than women with non-opioid SUD and women without
SUD (63.2% vs 66.4% and 71.1%). Compared to women with OUD, women without SUD had
higher odds of initiating most or moderately effective contraceptive methods than no method by
3, 6, and 12 months postpartum in multivariable (3 months: adjusted odds ratios [aOR] 1.71,
95% CI 1.31-2.24; 6 months: aOR 1.72, 95% CI 1.31-2.25; 12 months: aOR 1.84, 95% CI 1.402.43) and weighted (3 months: aOR 1.63, 95% CI 1.24-2.15; 6 months: aOR 1.51, 95% CI 1.12-
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2.03; 12 months: aOR 1.60, 95% CI 1.20-2.14) regression models. In multivariable models,
women with non-opioid SUD had higher odds of initiating most or moderately effective
contraceptive methods than no method by 3 months (aOR 1.34, 95% CI 1.01-1.78) and 12
months (aOR 1.37, 95% CI 1.02-1.84) postpartum. Multivariable models also showed that
women without SUD had higher odds of initiating most effective contraceptive methods than
moderately effective methods or no method at 12 months postpartum compared to women with
OUD (aOR 1.34, 95% CI 1.01-1.78).
Conclusion: OUD may be associated with decreased use of most and moderately effective
contraceptive methods in the postpartum period. More research is needed to understand the
differential postpartum contraceptive behaviors of women with OUD than women with other
SUD types.
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INTRODUCTION
Among women with substance use disorders (SUD), more than 7 out of every 10
pregnancies are unintended.1–5 Unintended pregnancy is associated with unfavorable
maternal and perinatal health behaviors and outcomes, such as delayed prenatal care
initiation, maternal anxiety and depression, and low birth weight.6,7 Many factors, such as
limited contraceptive access and inconsistent contraceptive use, are thought to play a role
in the high rates of unintended pregnancy in the United States (US).8
Several studies conducted in samples of non-pregnant, non-postpartum women
indicate that women with SUD use contraceptives less often, and use less effective
methods, than women without SUD.4,5,9–11 Whether this extends to women in the
postpartum period is not well known. Only one recent study, to our knowledge, has
examined the postpartum contraceptive behaviors of women with SUD while using a
comparison group of women without SUD. In a study by MacAfee and colleagues,
women reporting drug use during pregnancy were significantly less likely to use
contraception in the postpartum period than women who did not report prenatal drug use
(79.6% vs 88.1%).12 Pregnancy is considered a ‘window of opportunity’ and may provide
an optimal time to improve long-term maternal and child health through providing access
to care and planning for future pregnancies.
Prior US investigations of postpartum contraceptive behaviors of women with
SUD have largely been restricted to women with opioid use disorders (OUD). In these
studies, use of highly effective or effective methods by 3 months postpartum ranged from
25.5%-62%.13–15 In the sole study examining postpartum contraceptive use in a sample of
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women reporting risky use of other substances, 71.3% of study participants reported
using contraceptives at 3 months postpartum,3 which is higher than prevalence rates
reported in studies restricted to opioid-using populations and appears to be closer in line
with the findings reported by MacAfee et al.
Because women with OUD may differ from women with non-opioid SUD (e.g.
cocaine use disorder, methamphetamine use disorder) and women without SUD in
several important ways, including their sociodemographics, medical and mental health
comorbidities, and treatment needs and outcomes,16,17 it is plausible that the postpartum
contraceptive behaviors of women with OUD are different than those of women with
non-opioid SUD and women without SUD. However, based on existing research, it
remains unclear whether such differences exist. This study compared patterns of
postpartum contraceptive initiation among women with OUD, women with non-opioid
SUD, and women without SUD. We conducted this research to offer support for
clinicians providing reproductive health services to substance-using women of
childbearing age. Knowledge gained from this study may inform tailoring of
contraceptive counseling and provision for patients with OUD.
METHODS
Data and study population
We conducted a retrospective analysis of de-identified South Carolina (SC)
Medicaid claims data requested from the SC Office of Research and Statistics. These data
include detailed information about medical and pharmacy dispensing claims, as well as
patient demographic and enrollment data, for Medicaid beneficiaries during eligible
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periods. The Clemson University Institutional Review Board deemed this study exempt
from review.
The study cohort was selected from a database of women aged 15-44 years who
were enrolled in SC Medicaid between January 2000 and June 2018. From this source
population, we identified women who had at least one live birth delivery with continuous
enrollment from 60 months prior to delivery through 12 months postpartum. Restricting
the sample to women with continuous enrollment for 5 years before delivery allowed us
to ascertain important pre-pregnancy covariates, such as past contraceptive use, that are
highly correlated with postpartum contraceptive initiation. Similar to previously validated
methods,18 we identified live birth deliveries using diagnosis-related groups,
International Classification of Diseases, Ninth and Tenth Revisions (ICD-9 and ICD-10)
diagnosis and procedure codes, and Healthcare Common Procedure Coding System
(HCPCS) codes (Appendix D). We excluded births from twin or higher-order
pregnancies because contraceptive provision and use may differ for women with multiple
and singleton gestations. We further excluded deliveries that occurred in 2000-2004 or
after June 2017 because complete data were not available for these women. Of the
remaining births, only the first delivery for each woman was used in the analysis.
Exposure
Our exposure variable was SUD, defined as a diagnosis of alcohol or drug abuse
or dependence in the 5 years prior to delivery. We did not include tobacco in our
definition because it is poorly captured in administrative data.19 Women with SUD were
identified on the basis of ICD-9 or ICD-10 diagnosis codes in any position on >1
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inpatient or >2 outpatient or professional claims on different service dates (Appendix
A).20 We further identified women with SUD by searching medical and pharmacy claims
using HCPCS codes and National Drug Code (NDC) numbers for medications used treat
alcohol and opioid use.21 Because our primary interest was to examine differences in
postpartum contraceptive behaviors of women with and without OUD, we stratified
women without OUD into two groups, including women with non-opioid SUD and
women without SUD.
Outcomes
Outcomes included contraceptive initiation within the immediate postpartum
period and by 3, 6, and 12 months postpartum. From inpatient, outpatient, and
professional claims using ICD-9 and ICD-10 diagnosis and procedure codes, HCPCS
codes, and NDC codes (Appendix B codes), we identified the following contraceptive
methods: female sterilization, implants, intrauterine devices or systems (IUD/IUS),
injectables, oral pills, patch, ring, and diaphragm. We were unable to examine over-thecounter or no cost contraceptive methods, such as condoms, sponge, spermicide,
withdrawal, or natural family planning, that are not reimbursed by Medicaid. On the basis
of the NQF-endorsed performance measures,22 we categorized methods into most
effective (sterilization, implants, and IUD/IUS) and moderately effective (injectables,
oral pills, patch, ring, and diaphragm). Women who were not using one of these methods
were classified as using no method, although they may have been using a nonprescription or no cost method. If women used more than one method within the 12-
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month postpartum period, the first method initiated was used in the analysis given that
our objective was to examine initiation and not discontinuation.
Covariates
We a priori selected several demographic, pregnancy and reproductive health, and
medical covariates because of their potential association with SUD or postpartum
contraceptive initiation. These included age, race-ethnicity, marital status, county of
residence, plan type at delivery, year of delivery, number of prenatal care visits,
postpartum visit attendance, parity, past contraceptive use, and medical covariates. We
coded missing values of marital status as a separate category because this variable
contained a high percentage of missing data (27.5%).23,24 Using the US Department of
Agriculture’s 2013 Urban Influence Codes, we designated county of residence as
metropolitan (urban) or non-metropolitan (rural) (Appendix C).25 Plan type at delivery
included fee-for-service (FFS) or Medicaid managed care (MMC). Because of the high
correlation between parity and postpartum contraceptive use, we created a modified
parity variable based on the methodology from a previous study.13 Women with >1
pregnancies in the 5 years prior to delivery were classified as having >2 pregnancies. For
these women, we defined the outcome of the previous pregnancy, including live birth or
non-live birth (miscarriage, ectopic pregnancy, induced abortion, or stillbirth), using
ICD-9 and ICD-10 diagnosis codes and HCPCS codes (Appendix B). We also created a
variable to adjust for past contraceptive use, which was categorized into a most effective
reversible methods, moderately effective methods, or no method.22 If women used more
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than one contraceptive method in the years preceding delivery then the most recently
used method was selected.
For medical covariates, we created indicators for mental health comorbidities and
22 chronic conditions (breast cancer, malabsorptive bariatric surgery, venous
thromboembolism, valvular heart disease, systematic lupus erythematosus, liver cancer,
severe liver cirrhosis, ischemic heart disease, chronic hypertension, stroke, migraine with
aura, diabetes with and without complications, peripartum cardiomyopathy, malignant
gestational trophoblastic disease, epilepsy, ovarian cancer, endometrial cancer,
thrombogenic mutations, tuberculosis, sickle cell disease, schistosomiasis with fibrosis of
liver, and solid organ transplantation) that have been identified by the Centers for Disease
Control and Prevention (CDC) as US Medical Eligibility for Contraceptive Use.26
Conditions were defined as having a HCPCS code for the condition, or an ICD-9 or ICD10 diagnosis or procedure code for the condition in any field, on >1 inpatient or >2
outpatient or professional claims at least 30 days apart in the two years prior to delivery
(Appendix E).27 Exceptions included bariatric surgery and organ transplant, which only
needed one outpatient claim, and breast cancer, which was observed in the 5 years prior
to delivery.26
Statistical analysis
We summarized the distribution of covariates across women with OUD, women
with non-opioid SUD, and women without SUD using univariate and bivariate statistics.
Categorical variables were compared using chi-square tests. To compare contraceptive
initiation within the immediate postpartum period and by 3, 6, and 12 months postpartum
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among women with and without OUD, we constructed multivariable models adjusted for
all demographic, pregnancy and reproductive health, and medical covariates. Separate
models estimated adjusted odds ratios (OR) and 95% confidence intervals (CI) for two
binary outcomes: initiation of most or moderately effective methods vs no method and
initiation of most effective methods vs moderately effective methods or no method.
In addition to traditional covariate adjustment, we applied propensity score (PS)
weighting to balance women with OUD, women with non-opioid SUD, and women
without SUD on baseline covariates. We used inverse probability of treatment weighting
(IPTW), which is one application of PS weighting that uses the PS to form a weight for
each individual in the sample, to determine the average treatment effect on the treated
(ATT). When estimating ATT, the weight equals 1 for subjects in the treatment group
and the odds of receiving the treatment for subjects in the control group.28 In this study,
women with OUD received a weight of 1 while women in the comparison groups
received a weight equal to the odds of having an OUD. This technique allowed us to
estimate the effect of having an OUD on postpartum contraceptive initiation for women
with non-opioid SUD and women without SUD.
To generate propensity scores and associated weights, we used the Toolkit for
Weighting and Analysis of Nonequivalent Groups (twang) package, as implemented
through SAS twang macros.29 This program uses generalized boosted models to estimate
PS weights and incorporates various diagnostic checks to assess the quality of weights
and balance of baseline covariates before and after weighting. A detailed description of
the methods used in this tool has been published elsewhere. 29,30
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Our PS models included all previously described demographic, pregnancy and
reproductive health, and medical covariates. We assessed covariate balance between
women with OUD and women in the comparison groups by calculating the difference in
means in units of the pooled standard deviation,31 or standardized difference, for each
covariate before and after PS weighting. The common threshold of <.10 was selected to
indicate an acceptable balance between groups.32 We evaluated the relationship between
OUD and postpartum contraceptive initiation using weighted logistic regression models.
As a final step, we calculated predicted probabilities of each outcome from weighted
regression models and tested for statistically significant differences.
To evaluate the robustness of our findings, we conducted several additional
analyses. First, to explore how using an altered sample selection criteria would impact
the estimates, we analyzed the data with a new study cohort that included women with 36
months of continuous Medicaid enrollment before delivery. While this resulted in more
women in the analytic sample, the trade-off was that we were unable to examine parity
and past contraceptive use prior to 3 years before delivery. Second, to ensure that
including missing values as a category in the marital status variable did not affect the
estimates, we performed complete case analysis. Third, we ran analyses with a restricted
exposure definition, which included receiving a SUD diagnosis in the 2 years prior to
delivery, to assess how a different exposure window would impact the precision of the
results. Third, in the subgroups of women with SUD, we repeated the main analysis while
additionally adjusting for polysubstance use disorder (PSUD) (yes vs no) to eliminate the
possibility that polysubstance use was responsible for the observed effects. Data were
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analyzed with SAS version 9.4 (SAS institute Inc., Cary, NC) and Stata version 14.1
(StataCorp).
RESULTS
The final study cohort included 23,326 women aged 15-44 years who had a
singleton live birth covered by South Carolina Medicaid between January 2005 and June
2017 and who met the continuous enrollment criteria (Figure 3.1). Of these women,
SUD diagnoses were present in 1,622 (6.95%) women, including 244 (1.05%) with OUD
and 1,378 (5.91%) with non-opioid SUD. At baseline, women with OUD more likely to
be older, white, and have MMC, >2 pregnancies prior to delivery, and mental health
comorbidities (P<.05 across all comparisons) than women with non-opioid SUD and
women without SUD (Table S3.1). In the weighted sample, the distribution of baseline
covariates between women with OUD and control groups were similar on the basis of
standardized differences <.10 (Table 3.1).
Before weighting, there were significant differences between women with OUD
and women without SUD in the prevalence of postpartum contraceptive use across all
time points (Table 3.2). No significant differences were observed in rates of postpartum
contraceptive initiation between women with OUD and women with non-opioid SUD.
Compared to other women, women with OUD were more likely to receive female
sterilization or implants and less likely to receive IUD/IUS, oral pills, or patch in the
postpartum period (Table S3.2). After weighting, significant differences remained
between women with OUD and women without SUD in initiation of most or moderately
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effective contraceptive methods by 3, 6, and 12 months postpartum (P<.05 for all
comparisons) (Table 3.2).
Multivariable models showed that women with non-opioid SUD and women
without SUD had significantly greater odds of initiating postpartum contraception of
most or moderately effective methods vs no method by 3 months (Non-opioid SUD: aOR
1.34, 95% CI 1.01-1.78); No SUD: aOR 1.71, 95% CI 1.31-2.24) and 12 months (Nonopioid SUD: aOR 1.37, 95% CI 1.02-1.84); No SUD: aOR 1.84, 95% CI 1.40-2.43)
postpartum than women with OUD (Table 3). This relationship was also significant for
the 6 month time point for women without SUD (aOR 1.72, 95% CI 1.31-2.25).
Moreover, women without SUD had higher odds of initiating most effective
contraceptive methods vs moderately effective methods or no method by 12 months
postpartum compared to women with OUD (aOR 1.34, 95% CI 1.01-1.78).
In weighted regression models, women without SUD compared to women with
OUD had significantly greater odds of initiating most or moderately effective
contraceptive methods vs no method within 3 months (aOR 1.63, 95% CI 1.24-2.15), 6
months ( aOR 1.51, 95% CI 1.12-2.03), and 12 months (aOR 1.60, 95% CI 1.20-2.14)
postpartum (Table 3.3). Among women with non-opioid SUD, none of the observed
associations attained statistical significance. Moreover, none of the results for the second
outcome of interest were statistically significant. In line with regression estimates,
predicted probabilities of initiating most or moderately effective contraceptive methods
by 3, 6, and 12 months postpartum were significantly greater for women without SUD
than women with OUD (P<.01 for all comparisons) (Figure 3.2). Predicted probabilities
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of initiating most effective contraceptive methods vs moderately effective methods or no
method were not significant for any of the observed time points (Figure 3.3).
When data were analyzed using alternate sample selection criteria, the magnitude
of associations were smaller than those observed in the main analysis (Table S3.3).
However, results remained statistically significant. Women without SUD had
significantly higher odds of initiating most or moderately effective methods by 3 months
(aOR 1.47, 95% CI 1.21-1.77), 6 months ( aOR 1.42, 95% CI 1.18-1.72), and 12 months
(aOR 1.48, 95% CI 1.22-1.81) postpartum in comparison to women with OUD. Complete
case analysis produced slightly stronger point estimates than the main analysis (Table
S3.4). More associations were statistically significant in analyses that used a restricted
exposure definition (Table S3.5). Both comparison groups had higher odds of initiating
most effective methods vs moderately effective methods or no method within 3 months
(Non-opioid SUD: aOR 1.65, 95% CI 1.06-2.56); No SUD: aOR 1.65, 95% CI 1.10-2.50)
and 12 months (Non-opioid SUD: aOR 1.54, 95% CI 1.01-2.34); No SUD: aOR 1.63,
95% CI 1.10-2.41) postpartum than women with OUD. Adjusting for PSUD in the
subgroup of women with SUD strengthened the magnitude of the observed associations.
Results of both outcomes for the 12-month time point reached statistical significance in
multivariable models (Most or moderate vs no method: aOR 1.40, 95% CI 1.01-1.95;
Most vs moderate or no method: aOR 1.44, 95% CI 1.03-2.03) (Table S3.6).
DISCUSSION
In this retrospective cohort analysis, we found that women with OUD were less likely
than women without OUD, including women with non-opioid SUD and women without
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SUD, to initiate most or moderately effective contraceptive methods within the extended
postpartum period. OUD was not associated with decreased contraceptive use in the
immediate postpartum period. The directions of associations were similar in
multivariable and weighted logistic regression models. However, PS weighting
attenuated the magnitude of the observed associations and only the results for comparison
group women without SUD remained statistically significant in the main analysis.
Supplemental analyses demonstrated that associations between OUD and
decreased contraceptive initiation were robust to altered sample selection criteria, a
narrower exposure definition, and a different model specification. The results were
similar in a larger sample of women with fewer years of continuous enrollment. Because
relatively few women remain continuously enrolled in Medicaid for 5 years, these
findings may be generalizable to a broader set of women with SUD. Of note, many of
the observed associations reached statistical significance when SUD was defined as
receiving a diagnosis in the 2 years instead of 5 years before delivery. This suggests that
the postpartum contraceptive behaviors of women with OUD may be influenced by their
stage of addiction and treatment.
Our study builds on research examining postpartum contraceptive use in women
with SUD. Consistent with other reports,14,15 we found that 51.6% of women with OUD
initiated most or moderately effective contraceptive methods by 3 months postpartum,
which is double that of Pennsylvania Medicaid-enrolled women with OUD (25.5%).13
Our data also show that 30.7% of women with OUD obtained female sterilization or
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LARC methods by 3 months postpartum, which is substantially higher than the 7.4%
reported among Pennsylvania Medicaid-enrolled women.13
Only one US study has examined contraceptive outcomes among women with
SUD past 90 days postpartum. In that study, two-thirds of participants reported using any
contraceptive method at 12 months.3 We found similar rates of use of most or moderately
effective methods for women with OUD (63.2%) and women with non-opioid SUD
(66.4%) by 12 months postpartum. However, there were notable differences in the types
of methods reported. In our sample, fewer women received injectables or IUD/IUS and
more women received oral pills.
Similar to McAfee et al,12 we found that women without SUD were more likely to
use contraceptives in the postpartum period than women with SUD, specifically women
with OUD. Though, prevalence rates of most or moderately effective contraceptive use
by 3 months postpartum were lower among women in our sample. Our results are likely
underestimated given our data source and inability to examine contraceptive methods that
are not reimbursed by Medicaid.
Any combination of patient or provider factors could explain these findings. Some
women with OUD have a low perceived risk of pregnancy due to past infertility,
menstrual irregularities, or low libido associated with opioid use33,34 and consequently
could be disinclined to initiate postpartum contraception. Moreover, women with OUD
may experience ambivalence towards pregnancy or preventing pregnancy,1 which could
contribute to a lack of motivation in starting or continuing contraceptives. Even in the
absence of pregnancy ambivalence, women with OUD may find it difficult to take a
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proactive approach to preventing pregnancy34 or desire pregnancy as a means of
achieving sobriety or accessing treatment.35,36 Alternatively, women with non-opioid
SUD may have a stronger desire than women using prescription opioids to delay or
prevent future pregnancies due to homelessness, social instability, or risky life situations.
It is also possible that providers tailor discussions around contraceptive methods
differently for women with alcohol use disorder because of the teratogenic potential of
alcohol or for women with SUD who use illicit substances rather than prescription drugs
such as opioids.
This study should be replicated with other state or national data to establish
generalizability. If the results reported here hold in future studies, they would have
important implications for clinical research and practice. Women with OUD commonly
experience personal, interpersonal, and systems-level barriers to contraceptive uptake and
continued use.2,10,37 Developing and evaluating innovative strategies aimed at increasing
family planning access and services for women with OUD who desire pregnancy
prevention is an important area for future research. Providers should be aware that
women with OUD may be less inclined to use contraceptives than non-opioid substance
using patients or patients without SUD and provide family planning counseling and
education accordingly. In the meantime, providers should aim to foster trust with all
patients with SUD by providing empathetic, compassionate family planning care using a
patient-centered approach.
Strengths and limitations
This study has several strengths. Previous studies examining postpartum
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contraceptive use among women with SUD have been limited by their lack of
comparison populations.9 We created two similar comparison groups for women with
OUD by using statistical methods for causal inference. Our analysis also accounted for
past medical and reproductive health factors that could influence postpartum
contraceptive initiation. However, we were unable to account for events that occurred
outside of this period, such as LARC insertion or sterilization, which may have impacted
the study findings. In addition, we present a novel finding of the role of SUD type on
postpartum contraceptive use outcomes.
This study also has limitations. Findings may not be generalizable to Medicaidenrolled women in other states, women with private or no insurance, or women with noncontinuous Medicaid enrollment. This study is subject to limitations of claims data,
including coding inaccuracies or missing data, misclassification bias, and reliance on
health conditions that are captured in the administrative billing records. Substance use, in
particular, is prone to misclassification and under-reporting because it requires that
providers uncover or patients disclose sensitive or illicit behaviors. However, any
misclassification of women with SUD as non-users in this study would likely bias our
findings toward the null. Finally, as with any observational study design, we could not
completely eliminate residual confounding from unobserved factors.
CONCLUSION
Current evidence supports that women with OUD face extensive barriers to
contraceptive use, but more research is needed to understand the patient and provider
factors that are associated with the findings presented herein. In particular, the differential
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contraceptive behaviors of women with OUD and women with non-opioid SUD merit
further study. Future research should also examine the extent to which OUD is associated
with higher rates of postpartum contraceptive non-adherence and discontinuation.
Ensuring that women with OUD and other SUD have equitable access to family planning
services and counseling is critical for advancing the health of mothers and babies and
increases the likelihood of lifelong positive outcomes. For women with SUD who desire
pregnancy prevention, new and innovative strategies that optimize family planning
outcomes while supporting women’s reproductive equity are needed.
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Figure 1. Flow diagram illustrating selection criteria for the study cohort.
828,528 Women aged 15-44 years
enrolled in South Carolina Medicaid
(January 2000-June 2018)

28,484 Women with at least
one live birth delivery and continuous
enrollment from 60 months
before to 12 months after delivery
(40,780 deliveries)
17,454 Deliveries excluded
3,497 Births from multiple
pregnancies
7,377 Deliveries in 2000-2004
1,416 Deliveries after June 2017
8,164 Subsequent deliveries
23,326 Women with a singleton live
birth included in the study cohort
(23,326 deliveries)

1,622 Women with a
substance use disorder

244 Women with an
opioid use disorder

21,704 Women without a
substance use disorder

1,378 Women with a non-opioid
substance use disorder
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Table 3.1. Demographic, pregnancy and reproductive health, and medical covariates of South Carolina Medicaid-enrolled
women aged 15-44 years with and without an opioid use disorder, after propensity score weighting, 2005-2017 (n=23,326)
Covariates
Demographic
Age group (years)
15-19
20-24
25-34
35-44
Race
Non-Hispanic white
Non-Hispanic black
Hispanic/Latino
Other race-ethnicity*
Marital status
Single
Married
Not married or separated
Unknown
Missing
County of residence†
Rural
Urban
Pregnancy and reproductive health
Plan type
Medicaid managed care
Fee-for-service
Year of delivery
2005
2006
2007
2008
2009
2010

OUD
(n=244)
n (%)

Non-opioid SUD
(n=1,378)
n (%)

No SUD
(n=21,704)
n (%)

35 (14.3)
50 (20.5)
139 (57.0)
20 (8.20)

34.3 (15.8)
42.6 (19.6)
120.8 (55.7)
19.2 (8.86)

37.2 (15.7)
48.3 (20.4)
131.9 (55.6)
19.8 (8.35)

198 (82.5)
26 (10.8)
2 (0.83)
14 (5.83)

175.3 (81.6)
27.2 (12.7)
1.01 (0.47)
11.2 (5.24)

190.9 (81.8)
28.9 (12.4)
1.09 (0.47)
12.6 (5.41)

145 (59.4)
10 (4.10)
5 (2.05)
18 (7.38)
66 (27.1)

126.3 (58.2)
11.1 (5.10)
5.71 (2.63)
13.3 (6.13)
60.5 (27.9)

139.7 (58.9)
12.0 (5.04)
4.59 (1.94)
16.6 (7.00)
64.3 (27.1)

69 (29.2)
167 (70.8)

54.8 (26.1)
155.5 (73.9)

64.8 (28.1)
165.5 (71.9)

167 (68.4)
77 (31.6)

147.9 (68.2)
69.1 (31.8)

158.6 (66.9)
78.5 (33.1)

17 (6.97)
5 (2.05)
20 (8.20)
17 (6.97)
14 (5.74)
9 (3.69)

13.8 (6.34)
7.87 (3.62)
18.3 (8.42)
13.1 (6.05)
12.2 (5.61)
12.0 (5.51)

14.6 (6.18)
9.05 (3.82)
18.4 (7.77)
13.9 (5.87)
13.8 (5.84)
12.1 (5.11)
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Absolute Standardized Differences
Before weighting After weighting
.67

.03

.59

.008

.08

.02

.13

.07

.36

.03

.54

.04

2011
2012
2013
2014
2015
2016
2017
Number of prenatal visits
0-1
2-3
4-7
>8
Postpartum visit‡
Yes
No
Parity§,||
>2
Live birth¶
Non-live birth¶
<2
Past contraceptive use§
Most effective reversible methods
Moderately effective method
No method
Medical
Mental health comorbidities
Chronic conditions#
0
1
>2

11 (4.51)
14 (5.74)
16 (6.56)
22 (9.02)
38 (15.6)
43 (17.6)
18 (7.38)

9.85 (4.54)
13.6 (6.26)
11.4 (5.28)
21.3 (9.82)
34.3 (15.8)
35.7 (16.5)
13.6 (6.25)

9.92 (4.18)
12.1 (5.09)
17.2 (7.24)
23.1 (9.74)
33.4 (14.1)
43.6 (18.4)
16.0 (6.74)

62 (25.4)
62 (25.4)
73 (29.9)
47 (19.3)

56.8 (26.2)
45.6 (21.0)
69.3 (31.9)
45.2 (20.8)

63.7 (26.8)
55.5 (23.4)
68.9 (29.1)
50.0 (20.6)

59 (24.2)
185 (75.8)

53.7 (24.7)
163.3 (75.3)

59.3 (25.0)
177.8 (75.0)

96 (39.3)
28 (11.5)
120 (49.2)

85.5 (39.4)
23.5 (10.8)
108.0 (49.8)

93.0 (39.2)
27.0 (11.4)
117.2 (49.4)

11 (4.51)
51(20.9)
182 (74.6)

10.7 (4.93)
43.7 (20.1)
162.6 (74.9)

11.2 (4.70)
49.3 (20.8)
176.7 (74.5)

161 (66.0)

140.3 (64.7)

153.7 (64.8)

210 (86.1)
29 (11.9)
5 (2.05)

184.3 (84.9)
29.5 (13.6)
3.21 (1.48)

207.9 (87.7)
26.1 (11.0)
3.15 (1.33)

OUD, opioid use disorder; Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder.
Percentages may not add to 100% due to rounding.
*
Includes Asian, Native American, and more than one race-ethnicity.
†
Derived using the United States Department of Agriculture’s Urban Influence Codes.
‡
Within 3 months following delivery.
§
Based on claims in the 5 years prior to delivery.
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.05

.04

.16

.02

.18

.02

.02

.005

1.04
.23

.03
.06

||

Women with >1 pregnancies in the data were classified as having >2 pregnancies.
Outcome of the previous pregnancy for women with >1 pregnancies in the 5 years prior to delivery.
#
Includes breast cancer, malabsorptive bariatric surgery, venous thromboembolism, valvular heart disease, systematic lupus erythematosus, liver cancer,
severe liver cirrhosis, ischemic heart disease, chronic hypertension, stroke, migraine with aura, diabetes with and without complications, peripartum
cardiomyopathy, malignant gestational trophoblastic disease, epilepsy, ovarian cancer, endometrial cancer, thrombogenic mutations, tuberculosis, sickle
cell disease, schistosomiasis with fibrosis of liver, and solid organ transplantation.
¶
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Table 3.2. Postpartum use of most or moderately effective contraceptive methods or no method among South-Carolina
Medicaid enrolled women aged 15-44 years with and without an opioid use disorder, before and after propensity score
weighting, 2005-2017 (n=23,326)

Outcomes
Immediate
postpartum
Most‡
Moderate§
No method||
3 months
postpartum
Most‡
Moderate§
No method||
6 months
postpartum
Most‡
Moderate§
No method||
12 months
postpartum
Most‡
Moderate§
No method||

A. OUD
(n=244)
n (%)

Unweighted sample
B. Non-opioid
SUD
A vs
C. No SUD
(n=1,378)
B*
(n=21,704)
n (%)
P
n (%)

A vs
C*
P

.06
54 (22.1)
14 (5.74)
176 (72.1)

222 (16.1)
76 (5.52)
1,080 (78.4)

75 (30.7)
51 (20.9)
118 (48.4)

369 (26.8)
373 (27.1)
636 (46.2)

82 (33.6)
61 (25.0)
101 (41.4)

401 (29.1)
427 (31.0)
550 (39.9)

86 (35.3)
68 (27.9)
90 (36.9)

432 (31.4)
482 (35.0)
464 (33.7)

A. OUD
(n=244)
n (%)

Weighted sample
B. Non-opioid
SUD
A vs
C. No SUD
(n=1,378)
B*,†
(n=21,704)
n (%)
P
n (%)

<.001
2,587 (11.9)
1,558 (7.18)
17,559 (80.9)

.11

.91
54 (22.1)
14 (5.74)
176 (72.1)

50.9 (22.9)
11.2 (5.03)
160.2 (72.1)

75 (30.7)
51 (20.9)
118 (48.4)

73.2 (35.5)
42.7 (20.7)
90.4 (43.8)

82 (33.6)
61 (25.0)
101 (41.4)

78.1 (37.7)
49.0 (23.6)
80.0 (38.6)

86 (35.3)
68 (27.9)
90 (36.9)

81.3 (40.3)
53.3 (26.5)
67.0 (33.2)

<.001
5,151 (23.7)
7,489 (34.5)
9,064 (41.8)

.14

.10

.002
74.5 (34.7)
62.0 (28.9)
78.2 (36.4)

.56

<.001
6,291 (29.0)
9,136 (42.1)
6,277 (28.9)

.84
50.2 (21.1)
12.2 (5.13)
175.9 (73.8)

.40

<.001
5,705 (26.3)
8,426 (38.8)
7,573 (34.9)

.02
79.4 (37.2)
65.9 (30.9)
68.0 (31.9)

.40

.01
79.3 (40.4)
64.5 (32.9)
52.5 (26.8)

OUD, opioid use disorder; Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder.
Percentages may not add to 100% due to rounding.
*
P values are two-tailed with <.05 indicating statistical significance.
†
P values obtained using the Rao-Scott chi-square statistic to account for propensity score weighted data.
‡
Most effective contraceptive methods include female sterilization, implants, and intrauterine devices or systems.
§
Moderately effective contraceptive methods include injectables, oral pills, patch, ring, and diaphragm.
||
Includes methods, such as condoms, sponge, spermicide, withdrawal, or natural family planning, not covered under the Medicaid program.
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A vs
C*,†
P

Table 3.3. Results from multivariable and propensity score weighted logistic regression models examining postpartum
contraceptive initiation among South Carolina Medicaid-enrolled women without an opioid use disorder compared to women
with an opioid use disorder, 2005-2017 (n=23,326)
Multivariable models*
Most or moderate‡ Most† vs moderate‡
vs no method§
or no method§
OR (95% CI)
OR (95% CI)
†

Immediate postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
3 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
6 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
12 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD

Weighted regression models
Most† or moderate‡ Most† vs moderate‡
vs no method§
or no method§
OR (95% CI)
OR (95% CI)

0.94 (0.68-1.30)
0.86 (0.64-1.16)

1.17 (0.82-1.68)
0.89 (0.64-1.25)

1.00 (0.71-1.43)
0.92 (0.68-1.24)

1.05 (0.71-1.53)
0.94 (0.68-1.30)

1.34 (1.01-1.78)
1.71 (1.31-2.24)

1.33 (0.97-1.83)
1.23 (0.99-1.78)

1.20 (0.87-1.65)
1.63 (1.24-2.15)

1.24 (0.89-1.73)
1.20 (0.89-1.61)

1.29 (0.97-1.73)
1.72 (1.31-2.25)

1.30 (0.95-1.77)
1.31 (0.98-1.75)

1.12 (0.81-1.55)
1.51 (1.12-2.03)

1.20 (0.86-1.67)
1.17 (0.87-1.58)

1.37 (1.02-1.84)
1.84 (1.40-2.43)

1.29 (0.95-1.75)
1.34 (1.01-1.78)

1.18 (0.84-1.64)
1.60 (1.20-2.14)

1.24 (0.90-1.73)
1.25 (0.94-1.66)

OR, odds ratio; CI, confidence intervals OUD, opioid use disorder; Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder.
*
Multivariable models adjusted for age, race-ethnicity, marital status, county of residence, plan type at delivery, year of delivery, number of prenatal
visits, postpartum visit attendance and outpatient health care utilization in the postpartum period (excluding immediate postpartum), parity, past
contraceptive use, mental health comorbidities, and chronic conditions.
†
Most effective contraceptive methods include female sterilization, implants, and intrauterine devices or systems.
‡
Moderately effective contraceptive methods include injectables, oral pills, patch, ring, and diaphragm.
§
Includes methods, such as condoms, sponge, spermicide, withdrawal, or natural family planning, not covered under the Medicaid program.
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Figure 3.2. Predicted probabilities of initiating most or moderately effective contraceptive methods within the immediate
postpartum period and by 3, 6, and 12 months postpartum for women with non-opioid substance use disorders, women without
substance use disorders, and women with opioid use disorders. Compared to women with opioid use disorder, there were
significant differences in predicted probabilities for women without substance use disorders by 3, 6, and 12 months postpartum
(P<.01 for all comparisons).

80%
60%
40%
20%
0%

Immediate
postpartum

3 months
postpartum

6 months
postpartum

Opioid use disorder
Non-opioid substance use disorder
No substance use disorder

94

12 months
postpartum

Figure 3.3. Predicted probabilities of initiating most effective contraceptive methods within the immediate postpartum and by
3, 6, and 12 months postpartum for women with non-opioid substance use disorders, women without substance use disorders,
and women with opioid use disorders. Compared to women with opioid use disorders, there were no significant differences in
predicted probabilities for women without opioid use disorders at any of the observed time points.
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Table S3.1. Demographic, pregnancy and reproductive health, and medical covariates of South Carolina Medicaid-enrolled
women aged 15-44 years with and without an opioid use disorder, before propensity score weighting, 2005-2017 (n=23,326)
Covariates
Demographic
Age group (years)
15-19
20-24
25-34
35-44
Race
Non-Hispanic white
Non-Hispanic black
Hispanic/Latino
Other race-ethnicity*
Marital status
Single
Married
Not married or separated
Unknown
Missing
County of residence†
Rural
Urban
Pregnancy and reproductive health
Plan type
Medicaid managed care
Fee-for-service
Year of delivery
2005
2006
2007
2008
2009
2010

A. OUD
(n=244)
n (%)

B. Non-opioid SUD
(n=1,378)
n (%)

A vs B
Ph

C. No SUD
(n=21,704)
n (%)

<.001
35 (14.3)
50 (20.5)
139 (57.0)
20 (8.20)

511 (37.1)
335 (24.3)
448 (32.5)
84 (6.10)

198 (82.5)
26 (10.8)
2 (0.83)
14 (5.83)

711 (52.2)
531 (39.0)
15 (1.10)
104 (7.64)

145 (59.4)
10 (4.10)
5 (2.05)
18 (7.38)
66 (27.1)

768 (55.7)
62 (4.50)
21 (1.52)
96 (6.97)
431 (31.3)

69 (29.2)
167 (70.8)

318 (23.6)
1032 (76.4)

167 (68.4)
77 (31.6)

793 (57.6)
585 (42.5)

17 (6.97)
5 (2.05)
20 (8.20)
17 (6.97)
14 (5.74)
9 (3.69)

164 (11.9)
161 (11.7)
108 (7.84)
67 (4.86)
64 (4.64)
71 (5.15)

<.05
8,229 (37.9)
5,627 (25.9)
6,836 (31.5)
1,012 (4.66)

<.001

<.001
7,238 (33.6)
13,216 (61.4)
296 (1.38)
769 (3.57)

.70

.29
13,028 (60.3)
1,173 (5.40)
189 (0.87)
1,378 (6.35)
5,936 (27.4)

.06

.63
5,948 (27.8)
15,428 (72.1)

.001

<.001
11,228 (51.7)
10,476 (48.3)

.0003
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A vs C
Ph

<.001
3,001 (13.8)
3,040 (14.0)
2,283 (10.5)
1,506 (6.94)
1,146 (5.28)
990 (4.56)

2011
2012
2013
2014
2015
2016
2017
Number of prenatal visits
0-1
2-3
4-7
>8
Postpartum visit‡
Yes
No
Parity§,||
>2
Live birth¶
Non-live birth¶
<2
Past contraceptive use§
Most effective reversible
methods
Moderately effective methods
No method
Medical
Mental health comorbidities
Chronic conditions#
0
1
>2

11 (4.51)
14 (5.74)
16 (6.56)
22 (9.02)
38 (15.6)
43 (17.6)
18 (7.38)

68 (4.93)
73 (5.30)
85 (6.17)
118 (8.56)
161 (11.7)
158 (11.5)
80 (5.81)

62 (25.4)
62 (25.4)
73 (29.9)
47 (19.3)

374 (27.1)
279 (20.3)
429 (31.1)
296 (21.5)

59 (24.2)
185 (75.8)

388 (28.2)
990 (71.8)

991 (4.57)
1,005 (4.63)
1,258 (5.80)
1,511 (6.96)
1,950 (8.98)
2,083 (9.60)
937 (4.32)
.33

.27
5,822 (26.8)
4,507 (20.8)
6,449 (29.7)
4,926 (22.7)

.20

.02
6,731 (31.0)
14,973 (69.0)

.03
96 (39.3)
28 (11.5)
120 (49.2)

423 (30.7)
171 (12.41)
784 (56.9)

.003
6,513 (30.0)
2,206 (10.2)
12,985 (59.8)

.69
11 (4.51)
51(20.9)
182 (74.6)

79 (5.73)
270 (19.6)
1,029 (74.7)

161 (66.0)

636 (46.2)

210 (86.1)
29 (11.9)
5 (2.05)

1,248 (90.6)
116 (8.42)
14 (1.02)

.94
915 (4.22)
4,709 (21.7)
16,080 (74.1)

<.001
.08

3,585 (16.5)
20,417 (94.1)
1,220 (5.62)
67 (0.31)

OUD, opioid use disorder; Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder.
Percentages may not add to 100% due to rounding.
*
Includes Asian, Native American, and more than one race-ethnicity.
†
Derived using the United States Department of Agriculture’s Urban Influence Codes.
‡
Within 3 months following delivery.
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<.001
<.001

§

Based on claims in the 5 years prior to delivery.
Women with >1 pregnancies in the data were classified as having >2 pregnancies.
¶
Outcome of the previous pregnancy for women with >1 pregnancies in the 5 years prior to delivery.
#
Includes breast cancer, malabsorptive bariatric surgery, venous thromboembolism, valvular heart disease, systematic lupus erythematosus, liver cancer,
severe liver cirrhosis, ischemic heart disease, chronic hypertension, stroke, migraine with aura, diabetes with and without complications, peripartum
cardiomyopathy, malignant gestational trophoblastic disease, epilepsy, ovarian cancer, endometrial cancer, thrombogenic mutations, tuberculosis, sickle
cell disease, schistosomiasis with fibrosis of liver, and solid organ transplantation.
||
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Table S3.2. Postpartum contraceptive use prevalence of most and moderately effective methods among South-Carolina
Medicaid enrolled women aged 15-44 years with and without an opioid use disorder, before propensity score weighting, 20052017 (n=23,326)

Outcomes
Immediate postpartum
Female sterilization
Intrauterine devices or systems
Implants
Injectables
Oral pills
Patch
Ring
Diaphragm
3 months postpartum
Female sterilization
Intrauterine devices or systems
Implants
Injectables
Oral pills
Patch
Ring
Diaphragm
6 months postpartum
Female sterilization
Intrauterine devices or systems
Implants
Injectables
Oral pills
Patch
Ring
Diaphragm
12 months postpartum
Female sterilization

A. OUD
(n=244)
n (%)
48 (19.7)
0 (0.00)
6 (2.46)
2 (0.82)
9 (3.69)
3 (1.23)
0 (0.00)
0 (0.00)
55 (23.0)
6 (2.46)
13 (5.33)
10 (4.10)
36 (14.8)
2 (0.82)
3 (1.23)
0 (0.00)
60 (24.6)
8 (3.28)
14 (5.74)
13 (5.33)
41 (16.8)
2 (0.82)
5 (2.05)
0 (0.00)
61 (25.0)

Unweighted sample
B. Non-opioid SUD
(n=1,378)
A vs B*
n (%)
P
.14
185 (13.4)
7 (0.51)
30 (2.18)
5 (0.36)
61 (4.43)
8 (0.58)
2 (0.15)
0 (0.00)
.08
246 (17.9)
63 (4.57)
60 (4.35)
114 (8.27)
203 (14.7)
29 (2.10)
27 (1.96)
0 (0.00)
.08
255 (18.5)
77 (5.59)
69 (5.01)
133 (9.65)
238 (17.3)
31 (2.25)
25 (1.81)
0 (0.00)
.05
264 (19.2)
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C. No SUD
(n=21,704)
n (%)

A vs C*
P
<.001

2,293 (10.6)
65 (0.30)
229 (1.06)
99 (0.46)
1,227 (5.65)
196 (0.90)
36 (0.17)
0 (0.00)
<.001
2,919 (13.5)
1,270 (5.85)
962 (4.43)
1,613 (7.43)
4,681 (21.6)
744 (3.43)
448 (2.06)
3 (0.01)
<.001
3,069 (14.1)
1,543 (7.11)
1,093 (5.04)
1,948 (8.98)
5,214 (24.0)
764 (3.52)
494 (2.28)
6 (0.03)
<.001
3,251 (15.0)

Intrauterine devices or systems
Implants
Injectables
Oral pills
Patch
Ring
Diaphragm

8 (3.28)
17 (6.97)
17 (6.97)
43 (17.6)
2 (0.82)
6 (2.46)
0 (0.00)

89 (6.46)
79 (5.73)
152 (11.0)
276 (20.0)
27 (1.96)
27 (1.96)
0 (0.00)

1,801 (8.30)
1,239 (5.71)
2,166 (9.98)
5,736 (26.4)
717 (3.30)
511 (2.35)
6 (0.03)

OUD, opioid use disorder; Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder.
Percentages may not add to 100% due to rounding.
*
P values are two-tailed with <.05 indicating statistical significance.
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Table S3.3. Results from analyses using alternate sample selection criteria to examine postpartum contraceptive initiation
among South Carolina Medicaid-enrolled women without an opioid use disorder compared to women with an opioid use
disorder, 2005-2017 (n=42,512)
Multivariable models*
Most or moderate‡ Most† vs moderate‡
vs no method§
or no method§
OR (95% CI)
OR (95% CI)
†

Immediate postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
3 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
6 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
12 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD

Weighted regression models
Most† or moderate‡ Most† vs moderate‡
vs no method§
or no method§
OR (95% CI)
OR (95% CI)

0.98 (0.76-1.24)
0.89 (0.71-1.10)

1.06 (0.82-1.38)
0.88 (0.69-1.11)

1.03 (0.79-1.31)
0.94 (0.76-1.17)

1.01 (0.78-1.33)
0.93 (0.73-1.17)

1.22 (1.00-1.50)
1.47 (1.21-1.77)

1.22 (0.98-1.52)
1.16 (0.95-1.43)

1.20 (0.96-1.50)
1.37 (1.12-1.67)

1.16 (0.92-1.47)
1.08 (0.88-1.33)

1.12 (0.91-1.38)
1.42 (1.18-1.72)

1.22 (0.98-1.51)
1.21 (0.99-1.48)

1.06 (0.84-1.33)
1.30 (1.05-1.60)

1.14 (0.90-1.44)
1.15 (0.93-1.43)

1.19 (0.96-1.47)
1.48 (1.22-1.81)

1.26 (1.01-1.56)
1.23 (1.01-1.51)

1.16 (0.91-1.47)
1.39 (1.12-1.72)

1.25 (0.99-1.57)
1.18 (0.95-1.45)

OR, odds ratio; CI, confidence intervals OUD, opioid use disorder; Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder.
Notes: Sample included women with continuous enrollment from 36 months before delivery to 12 months postpartum.
*
Multivariable models adjusted for age, race-ethnicity, marital status, county of residence, plan type at delivery, year of delivery, number of prenatal
visits, postpartum visit attendance and outpatient health care utilization in the postpartum period (excluding immediate postpartum), parity, past
contraceptive use, mental health comorbidities, and chronic conditions.
†
Most effective contraceptive methods include female sterilization, implants, and intrauterine devices or systems.
‡
Moderately effective contraceptive methods include injectables, oral pills, patch, ring, and diaphragm.
§
Includes methods, such as condoms, sponge, spermicide, withdrawal, or natural family planning, not covered under the Medicaid program.
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Table S3.4. Results from complete case analysis examining postpartum contraceptive initiation among South Carolina
Medicaid-enrolled women without an opioid use disorder compared to women with an opioid use disorder, 2005-2017
(n=23,326)
Multivariable models*
Most or moderate‡ Most† vs moderate‡
vs no method§
or no method§
OR (95% CI)
OR (95% CI)
†

Immediate postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
3 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
6 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
12 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD

Weighted regression models
Most† or moderate‡ Most† vs moderate‡
vs no method§
or no method§
OR (95% CI)
OR (95% CI)

1.08 (0.74-1.58)
0.98 (0.69-1.39)

1.40 (0.92-2.15)
1.03 (0.69-1.53)

1.02 (0.72-1.45)
0.92 (0.68-1.24)

1.08 (0.74-1.58)
0.94 (0.68-1.32)

1.49 (1.07-2.07)
1.82 (1.34-2.48)

1.37 (0.95-1.97)
1.27 (0.90-1.78)

1.19 (0.86-1.64)
1.69 (1.29-2.21)

1.22 (0.87-1.73)
1.17 (0.88-1.57)

1.40 (1.00-1.95)
1.81 (1.33-2.47)

1.34 (0.94-1.91)
1.23 (0.88-1.71)

1.08 (0.78-1.51)
1.64 (1.25-2.16)

1.16 (0.83-1.63)
1.18 (0.89-1.57)

1.45 (1.03-2.04)
1.93 (1.40-2.64)

1.37 (0.96-1.95)
1.34 (0.97-1.87)

1.15 (0.82-1.62)
1.66 (1.25-2.20)

1.20 (0.86-1.67)
1.23 (0.93-1.62)

OR, odds ratio; CI, confidence intervals OUD, opioid use disorder; Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder.
*
Multivariable models adjusted for age, race-ethnicity, marital status, county of residence, plan type at delivery, year of delivery, number of prenatal
visits, postpartum visit attendance and outpatient health care utilization in the postpartum period (excluding immediate postpartum), parity, past
contraceptive use, mental health comorbidities, and chronic conditions.
†
Most effective contraceptive methods include female sterilization, implants, and intrauterine devices or systems.
‡
Moderately effective contraceptive methods include injectables, oral pills, patch, ring, and diaphragm.
§
Includes methods, such as condoms, sponge, spermicide, withdrawal, or natural family planning, not covered under the Medicaid program.
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Table S3.5. Results from sensitivity analyses using a restricted exposure definition to examine postpartum contraceptive
initiation among South Carolina Medicaid-enrolled women without an opioid use disorder compared to women with an opioid
use disorder, 2005-2017 (n=23,326)
Multivariable models*
Most or moderate‡ Most† vs moderate‡
vs no method§
or no method§
OR (95% CI)
OR (95% CI)
†

Immediate postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
3 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
6 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
12 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD

Weighted regression models
Most† or moderate‡ Most† vs moderate‡
vs no method§
or no method§
OR (95% CI)
OR (95% CI)

0.88 (0.58-1.36)
0.86 (0.57-1.27)

1.12 (0.69-1.81)
0.94 (0.60-1.47)

1.20 (0.74-1.95)
0.93 (0.62-1.40)

1.37 (0.81-2.31)
0.98 (0.63-1.53)

1.44 (0.98-2.12)
1.84 (1.28-2.63)

1.65 (1.06-2.56)
1.65 (1.10-2.50)

1.56 (1.02-2.37)
1.78 (1.22-2.56)

1.63 (1.03-2.59)
1.57 (1.04-2.37)

1.22 (0.83-1.80)
1.64 (1.14-2.37)

1.46 (0.96-2.23)
1.52 (1.02-2.26)

1.40 (0.90-2.18)
1.54 (1.06-2.25)

1.48 (0.93-2.36)
1.45 (0.98-2.16)

1.50 (1.01-2.23)
2.00 (1.38-2.89)

1.54 (1.01-2.34)
1.63 (1.10-2.41)

1.89 (1.21-2.95)
1.73 (1.18-2.55)

1.77 (1.11-2.81)
1.43 (0.96-2.11)

OR, odds ratio; CI, confidence intervals OUD, opioid use disorder; Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder.
Notes: Exposure variable was ascertained by identifying specific diagnosis codes, procedure codes, and National Drug Code numbers (listed in
Appendix A) on medical and pharmacy claims in the 2 years prior to delivery. OUD: n= 129; Non-opioid SUD: n=838; No SUD: n=22,359.
*
Multivariable models adjusted for age, race-ethnicity, marital status, county of residence, plan type at delivery, year of delivery, number of prenatal
visits, postpartum visit attendance and outpatient health care utilization in the postpartum period (excluding immediate postpartum), parity, past
contraceptive use, mental health comorbidities, and chronic conditions.
†
Most effective contraceptive methods include female sterilization, implants, and intrauterine devices or systems.
‡
Moderately effective contraceptive methods include injectables, oral pills, patch, ring, and diaphragm.
§
Includes methods, such as condoms, sponge, spermicide, withdrawal, or natural family planning, not covered under the Medicaid program.
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Table S3.6. Results from subgroup analyses examining postpartum contraceptive initiation among South Carolina Medicaidenrolled women with a non-opioid substance use disorder compared to women with an opioid use disorder, 2005-2017
(n=1,622)
Multivariable models*
Most or moderate‡ Most† vs moderate‡
vs no method§
or no method§
OR (95% CI)
OR (95% CI)
†

Immediate postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
3 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
6 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD
12 months postpartum
Non-opioid SUD vs OUD
No SUD vs OUD

Weighted regression models
Most† or moderate‡ Most† vs moderate‡
vs no method§
or no method§
OR (95% CI)
OR (95% CI)

1.09 (0.77-1.55)
NA

1.20 (0.82-1.77)
NA

1.07 (0.74-1.56)
NA

1.11 (0.75-1.66)
NA

1.33 (0.98-1.83)
NA

1.43 (1.01-2.02)
NA

1.25 (0.91-1.72)
NA

1.26 (0.90-1.77)
NA

1.28 (0.93-1.76)
NA

1.41 (1.00-1.99)
NA

1.20 (0.86-1.66)
NA

1.27 (0.90-1.79)
NA

1.40 (1.01-1.95)
NA

1.44 (1.03-2.03)
NA

1.23 (0.88-1.72)
NA

1.29 (0.93-1.79)
NA

OR, odds ratio; CI, confidence intervals OUD, opioid use disorder; Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder;
NA, not applicable.
Notes: Propensity score and outcome models included polysubstance use (yes vs no) in the model specification.
*
Multivariable models adjusted for age, race-ethnicity, marital status, county of residence, plan type at delivery, year of delivery, number of prenatal
visits, postpartum visit attendance and outpatient health care utilization in the postpartum period (excluding immediate postpartum), parity, past
contraceptive use, mental health comorbidities, chronic conditions, and polysubstance use.
†
Most effective contraceptive methods include female sterilization, implants, and intrauterine devices or systems.
‡
Moderately effective contraceptive methods include injectables, oral pills, patch, ring, and diaphragm.
§
Includes methods, such as condoms, sponge, spermicide, withdrawal, or natural family planning, not covered under the Medicaid program.
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CHAPTER FOUR
“WE’RE NOT THE CAPTAIN OF THE SHIP, THE PATIENT IS”:
HEALTH CARE PROVIDERS’ CONTRACEPTIVE COUNSELING PRACTICES
FOR PATIENTS WITH SUBSTANCE USE DISORDERS
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ABSTRACT
Objective: Women with substance use disorders (SUD) have high rates of unintended
pregnancy, yet little research exists on how health care providers perform contraceptive
counseling for their patients with SUD. This study explored health care providers’ selfreported contraceptive counseling practices for women with SUD.
Study Design: We conducted semi-structured qualitative interviews with a national,
purposive sample of medical doctors (n=10) and advanced practice nurses (n=14) in four
US Census Bureau-designated regions. Interviews were audio-recorded and transcribed
verbatim. A two-member team conducted thematic analysis in Atlas.to v8 using topdown (deductive) and bottom-up (inductive) codes to construct themes.
Results: Five major themes were identified. Providers reported timing contraceptive
discussions and tailoring information uniquely for their patients with SUD. They also
emphasized the importance of building interpersonal relationships and prioritizing
patients’ autonomy while counseling patients with SUD. Many providers perceived that
long-acting reversible contraceptives were more appropriate than short-acting reversible
contraceptive methods for women with SUD who may experience social instability in
their lives.
Conclusion: Providers reported several considerations for optimizing contraceptive
counseling for women with SUD. They emphasized the importance of providing
unbiased, patient-centered family planning services for this population.
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1. INTRODUCTION
Despite modern innovations in family planning technologies and service delivery,
many women with substance use disorders (SUD) in the United States (US) are not
accessing contraception. Women with SUD have lower overall rates of contraceptive use
[1–3] and a higher reliance on less effective methods [1,3,4] than women without SUD.
Though robust evidence is still lacking, they may also have poorer contraceptive
adherence patterns [3,5], which could partly explain high rates of unintended pregnancy
in this population. Across US studies, unintended pregnancy rates among women with
SUD typically exceed 75% [4,6,7], compared to approximately 45% in the general
population [8].
Integrating reproductive health services into SUD treatment locations has been
proposed as one solution to meet the contraceptive needs of women with SUD. While
research has shown the feasibility [9,10] and acceptability [9,11,12] of this strategy,
studies investigating integrated reproductive health/SUD treatment services have reported
mixed results on contraceptive use outcomes. In a recent study among pregnant women
with opioid use disorder (OUD), those who received integrated medication assisted
treatment (MAT) and women’s services, including family planning, were more likely to
use long-acting reversible contraceptives (LARC) within six weeks of delivery than
women in traditional MAT [13]. However, a more recent study among pregnant women
with OUD reported that co-location of prenatal care with MAT was not associated with
increased postpartum contraceptive uptake by the postpartum visit [14]. To our
knowledge, no similar studies among non-pregnant women have been conducted.
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Contraceptive counseling is another strategy to improve contraceptive outcomes
for women with SUD. Contraceptive counseling can help women overcome informationrelated barriers to accessing family planning, especially LARC, by providing them with
accurate information and education about the safety and efficacy of various methods.
Several studies have reported that women with SUD who are interested in using LARC
would benefit from generalized education about LARC methods and specific
communications related to their safety, efficacy, and side effects [4,15]. In studies
conducted among general populations, contraceptive counseling in clinical settings is
associated with increased contraceptive knowledge as well as improved contraceptive use
outcomes, including initiation, continuation, and correct use [16]. Research has also
demonstrated that contraceptive counseling impacts decision-making about method
choice [17] and that higher quality patient-provider communication is associated with
continuation of a chosen method [18].
The American College of Obstetricians and Gynecologists (ACOG) recommends
contraceptive counseling as a routine part of SUD treatment [19]. Yet, contraceptive
counseling approaches for women with SUD remains a largely unexplored area of
research. This study investigated health care providers’ self-reported contraceptive
counseling practices for women with SUD in varying stages of addiction recovery. Our
primary goal was to explore patient-provider communication within the context of
contraceptive provision.
2. MATERIALS AND METHODS
2.1 Sample and Recruitment
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After receiving approval from the Clemson University Institutional Review
Board, a purposive sample of women’s health providers was recruited from across the
US. In this study, providers were defined as health care practitioners with prescriptive
authority. Providers were eligible for participation in the study if they actively perform
contraceptive counseling for women with SUD. Providers that practiced in correctional
institutions were excluded (n=1) due to state-level differences in contraceptive services
delivery within correctional settings. To enhance sampling variation, we recruited
participants to represent a wide variety of health care specialties and geographic locations
in the US. The desired sample size for maximum variation was at least two medical
doctors (MD) and two advanced practice nurses (APN) from each of the US Census
Bureau’s four designated regions (i.e. Midwest, Northeast, Southeast, and West).
To recruit study participants, we contacted national and state professional
associations and consortiums of women’s health providers to request assistance in
reaching out to their members. Potential participants were introduced to the study through
a mix of direct email contact, social media, and digital newsletters and invited to schedule
a phone interview. Interested parties contacted a project team member by email or text
message or completed a Google Form to enroll. After eligibility was determined,
participants were emailed an informational letter about the study. No incentives were
offered for research participation. Recruitment continued until the target sample size was
reached.
2.2 Data Collection
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One project team member (E.C.) conducted semi-structured interviews lasting
approximately 30 minutes between February 2019 and May 2019. A moderator guide
was developed and pilot tested with two APN before starting data collection. After
revising items for clarity and length, the final guide consisted of six open-ended questions
that broadly queried providers about contraceptive counseling provision for women with
SUD. Providers were queried about multiple facets of counseling, including the context
in which counseling takes place, information shared at visits, and communication
approaches. We used probing questions to explore differences in the provision of
counseling for women in their active addiction as compared to those in recovery, as well
as for women without SUD. With participants’ consent, interviews were digitally
recorded and then transcribed verbatim by a professional transcription service. For
quality assurance, transcribed interviews were compared to original recordings and
corrected as needed.
2.3 Data Analysis
Data were analyzed using a thematic analysis approach, which is a commonly
used analysis technique for identifying and reporting patterns of meaning in data [20].
Using Braun and Clarke’s six phases to thematic analysis to guide the process, two
members of the study team (E.C. and S.H-S.) independently coded the transcripts by
applying empirical codes (inductive) and pre-existing codes based on the moderator
guide and a review of the literature (deductive). The team met during the coding process
to address consensus, develop new codes, and update the coding structure. After code
saturation was reached at 10 interviews, team members recoded all 24 transcripts using
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the final codebook. Codes were then collated and overall themes constructed, which were
discussed with the other authors who provided feedback on the interpretation of the
findings. ATLAS.ti 8 software [21] was used for all steps of the analysis.
3. RESULTS
Characteristics of the sample are displayed in Table 4.1. A total of 24 providers,
including 10 medical doctors and 14 APN, participated in the study. Participants were
nearly evenly distributed between the four US Census Bureau-designated regions, with
most providers residing in the Midwest (29.2%) and the fewest providers residing in the
Northeast (20.8%). A majority of providers were female (91.7%) and aged 35-44 years
(45.8%). More than three quarters of participants had been providing contraceptive care
to women with SUD for five or less years (41.7%) or between six and 15 years (37.5%).
Five major themes were constructed from deductive and inductive coding
processes: 1) timing contraceptive discussions; 2) tailoring information; 3) building
interpersonal relationships; 4) prioritizing patient autonomy; and, 5) advising on
contraceptive methods. Themes are summarized below using illustrative quotes from
participant interviews. Additional illustrative quotes for each theme are presented in
Table 4.2.
3.1 Timing contraceptive discussions
Of several providers who cared for pregnant women, some reported initiating prenatal
contraceptive counseling in the third trimester and others in the first trimester. Among
these providers, a majority mentioned discussing contraception at one or two visits only,
while a few mentioned discussing it at every prenatal care visit. Of providers who treated
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non-pregnant patients, many reported discussing contraceptives at each patient-provider
interaction, and others stated that it depends on the reason for the visit. One provider
explained the decision to not engage in contraceptive discussions with certain patients in
their active addiction:
“I feel like people come in for one really specific reason, especially if they’re actively
using. Sometimes they’re just in for, I had this exposure or you know, and they’re less
interested in kind of overall well-being or counseling about well-being and so, it’s not
appropriate in that time. They’re not open to it necessarily.”
Certified Nurse-Midwife, Northeast
Several providers suggested that contraceptive counseling is of lower importance than
other patient needs. These providers generally described waiting to discuss contraceptives
until after patients receive treatment for comorbid conditions or achieve stabilization in
substance abuse treatment. Some providers who serve pregnant women also discussed
postponing contraceptive counseling until after the first obstetric visit due to the limited
time that providers have with patients to address more important pregnancy related
topics. One provider described how medical priorities and time constraints influence
timing of contraceptive discussions with pregnant patients with SUD:
“If somebody is coming in and… getting their addiction under control, we probably
are not talking about contraception at that point. They’re pregnant. We’re trying to
get their addiction taken care of… It’s probably going to be the second, third, fourth
meeting with them that we then talk about that preventative stuff. And not because
it’s not important, it’s just because literally time constraints and what needs to be
taken care of at that point.”
Psychiatrist, Southeast
3.2 Tailoring information
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Most providers described sharing similar contraceptive information with all patients.
Contraceptive effectiveness, risks/benefits, side effects, contraindications, and safety
were commonly mentioned as discussion topics. Many providers also revealed sharing
information about pregnancy within the context of the patients’ SUD. They mentioned
discussing the risk of pregnancy complications, adverse pregnancy and birth outcomes,
and longer-term effects of prenatal substance exposure on the child. MAT medications
and dosing regimens were reported as additional counseling topics for women with OUD.
One provider described tailoring information based on the type of substance use
diagnosis:
“With opioid use disorder I’ll talk about things like neonatal abstinence syndrome,
irritability, and withdrawal and what that could look like. Other people are smoking
during their pregnancy and talking about complications, especially the
neurodevelopment of their child with exposure to THC. Same thing with alcohol as
well, talking about fetal alcohol syndrome… I have some ladies that I’ve had to
counsel about nicotine as well and things like cleft lip, cleft palate, just discussing
what exposure to the fetus in utero to these substances, complications that could
arise.”
Family Nurse Practitioner, Midwest
Several providers reported individualizing family planning communications for
patients with SUD. To initiate personalized counseling, providers described asking
patients open-ended questions about their reproductive goals or experiences with past
contraceptive use, and for pregnant women, about their pregnancy intentions after
childbirth. In an effort to help patients make informed decisions about pregnancy
planning or prevention, some providers also discussed engaging women who were in
their active addiction or in early recovery to consider how having children would fit into
their current situation or impact their recovery.
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3.3 Building interpersonal relationships
Many providers described the importance and complexities of building interpersonal
relationships with their patients with SUD. These providers discussed the history of
negative and punitive attitudes from the medical community toward pregnant women
who use substances. They mentioned that their patients with SUD are often distrustful of
health care professionals. To develop a good rapport with patients, many providers stated
that it is essential to present information in a neutral, unbiased manner. One provider
explained how contraceptive information is most effectively delivered to patients with
SUD:
“It’s a very nuanced discussion with every woman, but specifically with women in
recovery because it so easily can be interpreted by them as you saying the only thing
that’s going to help you in this world is for you not to have another child… It has to
be presented in such a way that women don’t feel like you are introducing the idea of
contraception in the setting of saying they shouldn’t be mothers again.”
Obstetrician-Gynecologist, Northeast
Several providers described how they build interpersonal relationships with their patients
with SUD. Strategies included establishing a friend-like rapport during patient-provider
interactions, framing discussions around pregnancy and parenting in the positive rather
than the negative, and showing genuine care and concern for the mother-baby dyad
instead of just the baby.
3.4 Prioritizing patient autonomy
Many providers stressed that their role in family planning is to provide information
about contraceptive options and not to influence their patients’ reproductive health or
contraceptive decisions. These providers emphasized that women with SUD, like other
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women, have the right to make their own reproductive choices and to select contraceptive
methods that best fit their lifestyles. Some providers expressed that empowering patients
to take charge of their own reproductive health is an important part of caring for patients
with SUD. One provider described her perceived role in providing contraceptive
counseling to patients with SUD:
“I feel like it’s my job to let them know that they are still in charge of their bodies and
that if they do want a pregnancy or they do want to become a parent, then that is okay
and we’ll support them through that.”
Family Medicine Physician, West
A majority of providers discussed the importance of prioritizing patient autonomy
when providing contraceptive services to women with SUD. Most stated that patient
autonomy assumes priority over counseling patients on highly effective methods. A few
of these providers mentioned advising against tubal ligations because of the permanency
of the procedure. Several providers shared that they must recognize and control their own
biases about patients’ reproductive health decisions to perform effective counseling for
women with SUD. One provider said:
“They still get to make their own choice no matter what I say or whatever. There are
people who, you know, have six or seven kids and they’re coming and they’ve had this
really complicated social life. They don’t want a tubal where you in your mind,
you’re going, you need this, you know. Because they’re in control of their life. So you
have to work with whatever, you know, however they see that going.”
Women’s Health Nurse Practitioner, Southeast
3.5 Advising on contraceptive methods
Many providers described counseling patients with SUD on the advantages of
LARC methods, especially women in their active addiction or in early recovery. Several
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providers discussed that their patients with SUD experience barriers that make it difficult
for them to comply with short-acting reversible contraceptive (SARC) methods. Common
barriers included housing instability, transportation or financial issues, reproductive
coercion by partners, low health care utilization, and poor postpartum follow-up. One
provider described the decision to counsel patients with SUD about LARC methods:
“I really don’t push it on them, it’s more of a discussion and letting them make the
decision, but I definitely encourage them to consider the benefits of a LARC method when
they are telling me and they’re hearing themselves tell me about a significant amount of
instability in their lives and the inability to control certain aspects of their lives in the
midst of addiction.”
Family Medicine Physician, West
Some providers perceived that their patients with SUD who had a longer time in
treatment and more stable living situations could do well with SARC methods. For
women with OUD maintained on daily buprenorphine, several providers perceived that
these patients would have improved adherence to oral contraceptives compared to other
patients with SUD. One provider explained:
“I think the person who is stable on their Buprenorphine and they’re already taking it
once per day, they can take their birth control pill at the same time. That person is
probably an okay option for using shorter term contraceptives.”
Certified Nurse-Midwife, Southeast
A few providers also mentioned emphasizing barrier methods for women who were in
their active addiction. However, most providers discussed the risk of sexually transmitted
infections and barrier methods similarly with all patients, regardless of SUD diagnosis.
4. DISCUSSION
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Providers described varying approaches to timing contraceptive discussions with
their patients with SUD. Primarily they reported postponing family planning care to a
point after patients achieve stability in medical care or in substance abuse treatment. For
obstetric providers, postponing family planning conversations was also related to limited
time and competing demands during antenatal care appointments. Although
recommendations are that women should receive family planning care at prenatal and
postpartum visits, there are currently no specific guidelines on how often or during which
visit antenatal contraceptive counseling should be performed [22]. In one study
examining contraceptive care preferences of low-income, underserved women,
researchers found that participants preferred short, frequent contraceptive counseling
discussions throughout the prenatal period [23]. No studies have examined whether such
a strategy could improve postpartum contraceptive use outcomes. However, national
survey data suggest that counseling provided in the prenatal and postpartum periods is
more effective for promoting contraceptive uptake than when it is provided in either
period alone [24]. Given the unique treatment needs of women with SUD, it is important
for future research to examine women’s preferences for the frequency and timing of
contraceptive discussions, as well as how these factors influence contraceptive uptake, in
this population.
Consistent with reproductive life planning approaches outlined by ACOG [25],
many providers initiated contraceptive discussions with their patients with SUD by
asking about future reproductive intentions. Providers described asking open-ended
questions to elicit information about patients’ reproductive health goals and engaging in
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personalized counseling about contraceptive methods based on their responses. Providers
also reported tailoring information about pregnancy uniquely for women with SUD and
empowering patients to make autonomous decisions about their own reproductive health
and fertility. These self-described practices are consistent with a patient-centered
approach to contraceptive counseling, which prioritizes individualized counseling to help
patients make informed choices about the best contraceptive methods for their situations
over counseling towards methods with the highest efficacy [26,27]. Prior research
indicates that patient-centered care can improve patient satisfaction and perceived quality
of care, build trust and understanding between clinicians and patients, and enhance and
facilitate collaborative decision making [28]. In the context of family planning care,
studies have found that patient-centeredness is aligned with patients’ preferences for
patient-provider communication [29,30] and associated with improved contraceptive use
outcomes [31].
Patient-centered contraceptive care may be an especially important consideration
for women with SUD. There is a long history in the US and elsewhere of practices of
stigma and discrimination toward persons who use drugs. While current evidence
recognizes addiction as a chronic, relapsing biologic disorder [32], there still exists a
widely held public view that people who use drugs are dangerous, unpredictable, and to
blame for their disease [33]. Society has responded to these narratives by developing and
implementing policies to criminalize and marginalize people who engage in drug use, a
burden that falls disproportionately on people of color and people in low socioeconomic
brackets. The capacity of women who use drugs to be fit mothers has further been called
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into question because of the potential of maternal substance use to cause fetal harm.
Pregnant drug users have been subject to legal and social interventions, such as
compulsory treatment, loss of parental custody, arrest, prosecution, and conviction, in the
name of protecting the fetus from the risks of prenatal drug exposure [34]. Providers in
this study were sensitive to the discrimination and stigmatization that women with SUD
may experience in health care settings and maintained that these practices create barriers
to seeking care and treatment within this population. To build trusting relationships with
their patients with SUD, providers discussed the importance of providing nonjudgmental, empathetic care and not pressuring patients to choose the most effective
contraceptive methods.
Even so, many providers perceived that LARC methods are the best contraceptive
options for some patients with SUD, particularly women in their active addiction or in
early recovery. This was not due to the substance use itself or the high risk of unintended
pregnancy among women with SUD. Rather, these providers asserted that based on their
medical experience women with multiple forms of instability in their lives have difficulty
sustaining user-dependent contraceptives. Past research indicates that women with SUD
experience unique barriers to contraceptive access and continuation that may not be
experienced by other women. Such barriers include a perceived low risk of pregnancy
from substance use [11,35–37], decreased health care utilization during periods of active
substance use [9,12], drug-induced sexual dysfunction or loss of interest in sex [35,37],
or desire to become pregnant as a means for achieving sobriety or accessing addiction
treatment [35,37]. Like other underserved, marginalized populations, women with SUD

119

may also experience significant intra-/inter-personal barriers, including co-occurring
psychiatric disorders, trauma exposure, and interpersonal violence, and systems-level
barriers to contraceptive use [9,35,38,39]. Notably, providers in this study believed that
women with OUD who were maintained on daily buprenorphine were more likely than
other patients with SUD to be compliant with daily oral contraceptives. Future research
that examines the relationship between MAT type and SARC adherence and continuation
among women with OUD may offer clinical guidance for providers who deliver family
planning care to this population.
To our knowledge, this is the first study to investigate how health care providers’
perform contraceptive counseling for women with SUD in a national sample of diverse
providers. These findings must be interpreted with several limitations in mind. A small
number of providers with varying specialties and from different regions of the US were
recruited into the study. Therefore, we were unable to draw conclusions about differences
in contraceptive care practices based on provider type or region. Because participants
self-selected into the interviews, it is likely that providers who responded to recruitment
advertisements have different perceptions of counseling patients with SUD than those
who did not respond, or than providers who do not provide contraceptive counseling to
patients with SUD. The study sample consisted of all Caucasian providers, and responses
given by these providers may not be generalizable to persons of other racial and ethnic
groups. Finally, practices described by the providers in our sample were self-reported and
may not be reflective of their actual contraceptive counseling practices for their patients
with SUD.
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5. CONCLUSION
This study examined health care providers’ contraceptive counseling practices for
women with SUD. While most providers in this study stressed the importance of not
providing differential counseling for any patient, they also described several important
considerations for providing contraceptive care to patients with SUD. These included
timing contraceptive discussions appropriately, tailoring pregnancy-related information,
providing non-judgmental, compassionate care, and respecting patients’ reproductive
autonomy. Providers also shared how the medical, treatment, and psychosocial needs of
their patients shape discussions around contraceptive methods. Though providers in this
study generally described engaging in patient-centered contraceptive counseling with
women with SUD, they also reported experiencing negative feelings towards women’s
reproductive health choices at times. This finding underscores the importance of
providers recognizing their own perceptions and views related to substance abuse and
preventing their own biases from influencing contraceptive provision for substance-using
patients. To understand the best counseling approaches for women with SUD, additional
research is needed to examine the family planning preferences, needs, and perspectives of
women in varying stages of addiction or recovery. Understanding when and how women
with SUD want to receive contraceptive counseling is critical to ensuring the delivery of
quality, patient-centered family planning care for this population.
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Table 4.1. Characteristics of health care providers in the sample (N=24)
Provider type
Medical doctor
Advanced practice nurse
Provider region*
Northeast
Midwest
South
West
Provider’s medical sub-/specialty
Physician**
Addiction medicine
Family medicine
Obstetrics and gynecology or maternal-fetal
medicine
Psychiatry
Nurse
Certified nurse-midwife
Family or adult nurse practitioner
Women’s health nurse practitioner
Psychiatric-mental health nurse practitioner
Age (years)
25-34
35-44
45-54
55-64
> 65
Gender
Female
Male
Race/ethnicity
Non-Hispanic white
Years contraceptive counseling women with SUD
<5
6-15
> 16
Average number of patients seen per week
< 50
50-80
81-125
> 125
Percentage of patients with a diagnosed SUD
< 25%
25-75%
> 75%

n

%

10
14

41.7
58.3

5
7
6
6

20.8
29.2
25.0
25.0

6
4

29.2
16.7

5
1

20.8
4.20

6
2
5
1

42.9
14.3
35.7
7.14

4
11
3
4
2

16.7
45.8
12.5
16.7
8.33

22
2

91.7
8.33

24

100

10
9
5

41.7
37.5
20.8

6
7
5
6

25.0
29.2
20.8
25.0

14
6
4

58.3
25.0
16.7

Abbreviations: SUD, substance use disorder
*Based on United States Census Bureau-designated regions
** Column does not add to 100% because providers can contribute to more than one category
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Table 4.2. Themes and additional illustrative quotes
Theme
Timing contraceptive discussions
Waiting

Illustrative Quotes

“You know, you want to kind of get them through that withdrawal or whatever they’re going through and get
stable and then talk to them about it [contraceptives].”
Women’s Health Nurse Practitioner, Southeast
“People that are just coming in, it’s almost like we’re focused on the here and now of stabilization where it’s,
hey you are not in a good place right now. We need to get you stabilized. When they’re stabilized, it’s okay,
what are your fertility goals?.”
Family Nurse Practitioner, Midwest

Postponing

“I think it’s just complete overload with all of the things they’re trying to accomplish every day and plan and
trying to balance everything and you know the overwhelming concern for social services kind of clouds
everything and they can’t really oftentimes can’t focus on other things than just getting through that initial
period.”
Obstetrician-Gynecologist, Northeast

Tailoring information
Contextualizing

“The counseling around contraception doesn’t change so much as the counseling around what it would look
like to be pregnant and to be parents.”
Family Medicine Physician, West

Engaging

“If they’re in active addiction… I definitely would warn them without being judgmental that if you think life is
tough now, just get pregnant…and seriously think about a pregnancy and how much that might compromise
or complicate your treatment at this time.”
Obstetrician-Gynecologist, Midwest
“One thing I do ask them is ‘if you were to get pregnant right now, would you continue the pregnancy or
would you terminate the pregnancy?’ And I think that’s an important piece for them to think through. Because
if they would never have an abortion, then what I’ll say to them is ‘I want you to not be in the position where
you have to make that choice.’”
Certified Nurse-Midwife, Midwest
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Building interpersonal relationships
Complexities

“We have such an important, painful history of coercing women into sterilization who use substances and
there still persists this kind of cultural and medical community belief that women who use drugs are unfit
mothers… and so, you know, I wouldn’t want it to be where somehow I was really laying it on heavy for
women in active use and them getting the impression that I didn’t want them to get pregnant because of their
substance use.”
Family Medicine Physician, West

Strategies

“We talk about all kinds of stuff that has absolutely nothing to do with why they’re there. And I think that
helps a lot. I know about their dogs. I know about their jobs. I know they had this terrible visit with their inlaws that they hate last week, you know what I mean? Just like personal stuff or some funny story about my
dogs because they know about my dogs and my kids and stuff too. So, it’s more of a, it’s a visit, but it’s also
social. So, I think that helps bring them back. It’s rare that my patients don’t come to their appointments.”
Certified Nurse-Midwife, Midwest
“A lot of women who struggle with substance use disorder have heard in the press or from other people that
when they’re pregnant what we care about is their baby. I really try to message that my priority is not just
getting you through this pregnancy, I want to see you healthy for the rest of your life. My priority is you and
if I’m doing my job, you have to be healthy. That, I think, helps women feel more comfortable, and yes, I care
about your baby, but I equally or even more care about what happens to you.”
Maternal-Fetal Medicine Physician, Midwest

Prioritizing patient autonomy
Provider role

“It is my job as a physician to help people to understand what are the pros and cons, what the risk/benefit is.
But then they’re still allowed to make the decision of getting pregnant while they’re using or continuing a
pregnancy despite their substance use or having an abortion because of their substance use.”
Family Medicine Physician, West
“I just try to really educate them. And really, that’s their decision. I’m not the one in their shoes. I can have
an opinion, but it’s not my job to offload my opinion on them.”
Certified Nurse-Midwife, Midwest

Recognizing
biases

“I know that there are times when I’m like, oh wow, I’d really love for you to be more healthy in terms of your
substance use before you get pregnant, but I don’t get to choose that for them.”
Family Medicine Physician, West
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Advising on contraceptive methods
LARC

“For those who are not far into recovery, I try to talk to them about, you know, the ease of having an IUD in
that they don’t have to worry about it. I’ll probably say, you know, your life is sort of crazy, are you having
anymore babies? Do you want babies? If you do, that’s fine with me, I don’t care, it doesn’t matter. But,
you’re out on the street and you’re living under a bridge and it’s very unlikely that you’re going to remember
to take birth control. So, for her, I probably would be a little bit more encouraging of an IUD…And if they say
to me no, my preference is for the pill, I’ll say, okay that’s cool, whatever, it’s all about choices.”
Certified Nurse-Midwife, Midwest
“I would suggest the long-acting reversible because usually their lives [women with SUD] are a little more
hectic.”
Obstetrician-Gynecologist, Southeast

SARC

“Women who are on Buprenorphine, I try to talk with them about, okay, if you really only feel comfortable
with the pill, then combine it with your Suboxone. They’re not going to forget their Suboxone. You know,
those folks actually could make it work. For folks who are not taking something regularly, I really sort of push
for the LARC.”
Obstetrician-Gynecologist, Northeast
“They’re able to take a pill every day, some of the ones that are well-managed, okay they can do that.”
Certified Nurse-Midwife, West

Barrier

“I focus more on the need for barrier contraception and the sexually transmitted infection risk in women who
are not in recovery.”
Maternal-Fetal Medicine Physician, Midwest

128

CHAPTER FIVE
CONCLUSION
The goal of this dissertation was to examine contraceptive provision and initiation
trends, patterns, and practices among reproductive-age women with and without SUD.
Aim 1 examined changes in contraceptive provision from 2000-2017 for South Carolina
Medicaid-enrolled women with and without SUD aged 15-44 at risk of unintended
pregnancy. Aim 2 compared postpartum contraceptive initiation patterns in South
Carolina Medicaid-enrolled women with and without OUD aged 15-44. Aim 3
investigated health care providers’ contraceptive counseling practices for reproductiveage women with SUD in varying stages of addiction recovery. The studies presented in
this dissertation collectively add to our understanding of how women with SUD are
provided with and use contraception during their childbearing years and may be useful to
inform public health and clinical interventions to improve access to and quality of
contraceptive services for women with SUD. Here we summarize the findings from each
chapter and conclude by discussing the clinical and public health implications of this
work and future research directions.
Overview of dissertation findings
Trends in contraceptive provision
Chapter 2 described changes in contraceptive provision from 2000-2017 for
reproductive-age women with and without SUD enrolled in SC Medicaid. This study
applied NQF-endorsed clinical performance measures for contraceptive care to calculate
annual unadjusted rates of MME and LARC provision for women with and with SUD.
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Percentages were stratified by patient characteristics to identify subgroups of women
with particularly low access (i.e. LARC provision less than 2%) to contraceptives during
the study period.
The percentage of SC Medicaid-enrolled women provided a MME or LARC
method increased substantially between 2000-2017. MME provision increased less for
women with SUD than women without SUD. However, a greater increase in LARC
provision was observed for women with SUD. Compared to other substance-using
women, women with OUD had the lowest increase in MME and LARC provision over
the study period. The percentage of women provided a MME method increased more for
women with SUD aged 15-20 compared to women without SUD of a similar age. In later
study years, adolescent women with SUD had the highest absolute rates of contraceptive
uptake across all age groups. Another important finding from this chapter includes that
adolescent women with SUD aged 15-17 had the greatest increase in MME provision
over the study period compared to other women of all age groups. Adolescent women
aged 18-20 had the greatest increase in LARC provision over the study period.
Patterns in postpartum contraceptive initiation
Chapter 3 examined the postpartum contraceptive behaviors of women with OUD
compared to women without OUD, including women with non-opoioid SUD and women
without SUD. Associations between OUD and postpartum contraceptive initiation were
examined at multiple time points, including within the immediate postpartum period and
by 3, 6, and 12 months postpartum. Multiple regression and IPTW analyses were used to
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obtain estimates, and predicted probabilities of MME initiation across time points were
calculated from weighted regression models and graphed.
Overall, findings indicated that women with OUD are less likely to initiate MME
contraceptive methods in the extended postpartum period than women with non-opioid
SUD and women without SUD. Multiple regression analysis showed that women with
non-opioid SUD and women without SUD had significantly higher odds of initiating
MME methods by 3 and 12 months postpartum than women with OUD. Women without
SUD also had higher odds of postpartum contraceptive initiation by 6 months
postpartum. Although the magnitude and direction of the estimates were similar in
weighted regression models, only the associations for women without SUD reached
statistical significance. Predicted probabilities were consistent with regression estimates
and showed that women with OUD have a lower probability of initiating postpartum
contraception by 3, 6, and 12 months postpartum in comparison to women without OUD.
Results from multiple sensitivity analyses confirmed the main findings.
Practices related to contraceptive counseling
Chapter 4 investigated health care providers’ self-reported contraceptive
counseling practices for their patients with SUD using a qualitative approach. Providers
were queried about multiple aspects of their contraceptive counseling for patients with
SUD, including the context in which counseling takes place, information shared at visits,
and communication approaches. Data were analyzed using a thematic analysis approach,
and five themes were constructed using inductive and deductive codes.
Providers described several important considerations for providing contraceptive
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care to patients with SUD, including, timing contraceptive discussions appropriately,
tailoring pregnancy-related information, providing non judgmental, compassionate care,
and respecting patients’ reproductive autonomy. Providers also shared how the medical,
treatment, and psychosocial needs of their patients shape discussions around
contraceptive methods. Because women with SUD have remarkably high rates of
unintended pregnancy, innovative strategies to improve contraceptive outcomes among
substance-using women are sorely needed. Appropriately timed, individualized
contraceptive counseling may be one strategy to improve family planning service
delivery and contraceptive outcomes for this population.
Concluding remarks
Dissertation strengths and limitations
This dissertation has several strengths and makes the following contributions to
the literature. First, chapter 2 demonstrated the utility of adapting the NQF-endorsed
CCM for use with subpopulations of women with SUD. This study also showed that the
CCM could reliably be used to calculate MME and LARC provision trends over time
with subpopulations. Second, no prior research has longitudinally examined
contraceptive provision for women enrolled in the SC Medicaid program. With 18 years
of administrative data, chapter 2 exhibited how trends in contraceptive provision among
Medicaid beneficiaries coincided with the rise of the opioid epidemic and how
contraceptive provision patterns changed over time according to participant
characteristics. Third, chapters 2 and 3 were conducted with large sample sizes, which
allowed for examination of the effect of SUD type on contraceptive provision and use
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outcomes. Because of the large sample size, we were able to create multiple comparison
groups for women with OUD in the chapter 3 study and to contribute an important
finding that women with OUD may initiate postpartum contraception less frequently than
women with other alcohol and drug disorders. Finally, chapter 4 included a diverse
national sample of women’s health providers and increased our understanding of how
contraceptive counseling is performed for women with SUD across the US.
This dissertation also has limitations. First, chapters 2 and 3 relied on
administrative billing data for ascertainment of SUD, which would only appear in the
data if the billed service was related to the SUD diagnosis. While it possible that we
underestimated the percentage of women with SUD, administrative data provide a
reasonable proxy for SUD identification and have been used extensively in substance
abuse research. Second, while Medicaid claims data contain comprehensive medical
information on beneficiaries, avoid biases inherent in self-report data, and are costeffective and convenient, they are collected for reimbursement and not research purposes
and are therefore subject to missing data and coding errors. Third, Medicaid data contain
limited information, so chapters 2 and 3 did not capture women who were using over-thecounter contraceptives or account for important variables, such as pregnancy intent or
quality of contraceptive counseling, that could influence contraceptive provision and use
outcomes. Fourth, it is possible that the results observed in chapters 2 and 3 were
attributable to misclassification of either the outcome or exposure variables, including
users classified as non-users or vice versa. Fifth, findings from this dissertation may have
limited generalizability. The quantitative study results may not be generalizable to
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reproductive-age women outside of the SC Medicaid program, such as women in other
states or women in SC who are uninsured or covered by private insurance, and findings
from chapter 4 may not be generalizable to other health care providers.
Implications and future research directions
The findings presented here have important clinical implications for contraceptive
care delivery for women with SUD. Providers should be aware that women with OUD
may be less inclined to use contraception than women with other alcohol and drug
disorders and should provide contraceptive counseling and education accordingly. Given
data limitations and time constraints, this research could not elucidate why women with
OUD may have differential contraceptive use behaviors than women with other types of
SUD. Women with OUD experience unique barriers to contraceptive use and adherence,
such as a perceived low risk of pregnancy due to irregular menses (1–5), which may be
responsible for the observed study findings. Though understanding these barriers is
beyond the scope of this dissertation, future efforts are needed to identify the particular
barriers that may contribute to differential contraceptive use for women with OUD
compared to women with other alcohol and drug disorders and to develop clinical and
public health interventions to address these barriers.
This dissertation found that provision of MME contraceptive methods among SC
Medicaid beneficiaries has increased less over time for women with SUD than women
without SUD. However, the opposite was true with regards to LARC. Consistent with
other research (6,7), these results suggest that women with SUD in our sample had poorer
uptake of and adherence to user-dependent forms of contraception. While the existing
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literature states that SUD is associated with decreased contraceptive use prevalence of
highly effective and effective methods (6,8), limited research to date has specifically
examined contraceptive adherence among women with SUD. The only two studies to
explore this topic have reported inconsistent findings (6,7). To develop and implement
effective interventions to facilitate improved contraceptive compliance among women
with SUD, it is important to assess patterns of adherence and discontinuation and factors
related to correct and consistent contraceptive use in this population.
Notably, our stratified analyses revealed that contraceptive provision was not
lower among women with SUD than women without SUD in adolescent women aged 1520. Absolute rates of contraceptive provision for adolescent women with SUD were
higher than for all other participants. This finding is inconsistent with national data
showing that contraceptive use is higher among older than younger women (9) and
suggests that younger women with SUD may not face the increased barriers to
contraceptive access and continued use that are experienced by older substance-using
women. Adolescent women with SUD may have increased family/social support and
resources, such as transportation or increased financial resources, that facilitate family
planning access and utilization. In addition, young people may have a regular pediatric or
adult care provider, which would increase opportunities for accessing and using highly
effective and effective contraceptive methods. Finding ways to keep women with SUD
who are in their later reproductive years engaged with reproductive health services and
the health care system in general is an important area of future research. SUD treatment
locations may offer an opportunity to reach women throughout their childbearing years,
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and co-location of family planning services into these settings has shown promise to
remove barriers to contraceptive access (10,11).
Several potential areas for future research emerged from the health care provider
interviews. Providers perceived that women with OUD taking daily buprenorphine may
have better adherence to oral contraceptives than women not taking buprenorphine.
Future research that examines the relationship between receipt of medication for OUD
(MOUD), type of medication, and contraceptive adherence could help clinicians provide
tailored contraceptive counseling for their patients with OUD. Studies examining the
effect of MOUD initiation during pregnancy on postpartum contraceptive outcomes are
also needed. Among providers that care for pregnant women, contraceptive counseling in
the antepartum is standard practice, but there is wide variation in the initiation, frequency,
and duration of prenatal contraceptive counseling. More research examining how these
factors influence postpartum contraceptive use outcomes may inform guidelines for
providing contraceptive counseling to pregnant women with SUD. A better
understanding is also needed of women’s preferences for the frequency and timing of
prenatal contraceptive discussions.
While the provider interviews revealed providers’ preferences related to
communication approaches and information discussed during contraceptive counseling,
additional studies are warranted to investigate patients’ preferences for patient-provider
communication during counseling interactions. Such information would be useful to
guide providers wishing to adopt a more patient-centered approach to contraceptive
counseling. While women with SUD who desire contraceptives should have access to
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them and many innovative strategies have been developed to increase that access, it is
important that providers and family planning advocates strive for reproductive equity
when engaging women with SUD in family planning discussions.
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Appendix A
Diagnosis and procedure codes used to identify alcohol and drug use disorders
Diagnosis or
procedure
Alcohol use
disorder
(non-opioid
substance use
disorder)

ICD-9
291.x, 303.xx,
305.0x

ICD-10
F10.1–F10.29,
HZ83ZZZ,
HZ93ZZZ,
HZ84ZZZ,
HZ94ZZZ
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HCPCS
J2315

NDC
00185003930, 68115068030,
51224020630, 68084029111,
68094085362, 54868557400,
00555090201, 16729008101,
16729008110, 52152010502,
00406117001, 42291063230,
43063059115, 47335032683,
00185003901, 00555090202,
51224020650, 52152010504,
52152010530, 00406117003,
50436010501, 47335032688,
68084029121, 10695004310,
10695004305, 62991124303,
62991124302, 62991124304,
60966024403, 62991124301,
60966014404, 60966034402,
38779088708, 51927275300,
62991312501, 62991312503,
62991312504, 52372075103,
51552073701, 63275990103,
55812033302, 63370015810,
49452483505, 58597840701,
58597840704, 55812033301,
62991312502, 00395808335,
51552073704, 58597840702,
63275990101, 63275990102,
63275990104, 63275990105,
63370015825, 38779088703,
38779088706, 58597840706,
51927360200, 63370015815,
52372075101, 52372075102,
00395808362, 49452483502,
63370015835, 38779088704,
38779088705, 49452483503,
00395808319, 51552073702,
51927437700, 55812033303,
49452483501, 51927354800,
65757030202, 65757030001,
63459030042, 51285027501,
51285027502, 00093535286,

51079024106, 00378633380,
68462043518, 60687012195,
42291010418, 68382056928,
60687012125, 00258400060,
51079024101, 10135063632,
54868529300, 00456333060,
00456333001, 00456333063,
47781060730, 64980017101,
00054035613, 60429019630,
60429019601, 64980017103,
00603343321, 00378414001,
00093503501, 00054035625,
00054035713, 00054035725,
00093503601, 00603343221,
00378414101, 64980017203,
64980017201, 51927312100,
49452264501, 38779197105,
38779197108, 51552109505,
38779197102, 38779197109,
54868503402, 51285052302,
54868503401, 54868503400,
51285052402
Cannabis use
disorder
(non-opioid
substance use
disorder)
Opioid use
disorder

304.3x, 305.2x

F12.1-F12.29

304.0x, 305.5x

F11.1-F11.29,
HZ81ZZZ,
HZ91ZZZ,
HZ84ZZZ,
HZ94ZZZ
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H0020,
H0016,
H0047,
J0570,
J0571,
J0572,
J0573,
J0574,
J0575,
J1230,
S0109,
J2315

70004037905, 61553012078,
66689071216, 00054355663,
66689069430, 00054039168,
66689069479, 66689069579,
00054039268, 64019055467,
66689069439, 00054355367,
64019055367, 00054355467,
24200028363, 61553013490,
23490779801, 66689089840,
00406254001, 68084097733,
68084097732, 64019053825,
23490779803, 70004038003,
24200028149, 00054355563,
66689071116, 00054457125,
10544037860, 66336017160,
42549057860, 54868285400,
68462080101, 63739000610,
52959038630, 63629377106,
42549057802, 42549057828,
54868494805, 16590067072,
55289081498, 52959038660,

42549057856, 66689081010,
16590067082, 10544037808,
55289081499, 42806031801,
55289081490, 23490587707,
42549057830, 68084073801,
54868494800, 54868494802,
00054855424, 00406577101,
16590067083, 66336017142,
55289081493, 63629377102,
63629377103, 63629377104,
68084073811, 13107008901,
23490587703, 54868494807,
35356083401, 00904653060,
49999083930, 67877011601,
16590067007, 16590067090,
10544037830, 54868494803,
66336017130, 66336017156,
55289081460, 54868285403,
54868494806, 16590067045,
16590067060, 10544037828,
63629377101, 00904653061,
23490587706, 23490587709,
42549057808, 00406577123,
35356083460, 35356083490,
49999083901, 49999083990,
00406577162, 16590067071,
52959038602, 52959038690,
63629377105, 35356083430,
68115057100, 49999083960,
55289081430, 54868494801,
61553014940, 61553014978,
66479053002, 67457021720,
17478038020, 52959043530,
42806031701, 68115057200,
10544037702, 49999096390,
13107008801, 42549057702,
42549057728, 00406575562,
16590068972, 43063022260,
54868570102, 43063022290,
35356083530, 35356083560,
00054457025, 00054855324,
16590068960, 66336017030,
66336017060, 49999096330,
23490587803, 35356083590,
66336017094, 54868570103,
00406575501, 60687021411,
66336017062, 68462080001,
16590068945, 66336017090,
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43063022298, 54868570100,
54868570101, 23490587801,
00406575523, 43063022293,
49999096360, 23490587802,
23490587809, 60687021401,
16590068990, 63629378801,
10544037728, 00406151056,
38779010403, 51927101700,
38779010404, 51552072801,
62991140803, 52372079603,
38779010405, 63275910005,
62991140801, 62991140802,
00054975085, 51552072804,
66689068155, 00054975088,
51552072802, 62991140805,
49452455301, 00406151057,
49452455302, 49452455303,
52372079602, 00406151059,
63275910004, 64019075088,
51552072806, 52372079601,
00054355344, 24200027503,
00054421925, 00054421825,
54868285402, 49999084030,
49999084060, 54868285401,
00406345434, 00406872510,
00406052710, 49999084130,
00406054034, 49999084160,
60687020933, 60687020932,
00409201203, 00409201232,
21695051510, 55390010010,
40042001001, 42023017905,
42023017901, 00093360121,
42858049340, 00093365721,
00093360140, 00093365740,
00093360221, 00093365840,
42858058640, 00093360240,
00093365821, 50383092493,
62756045983, 42858050103,
00054017613, 00093537856,
68308020230, 35356055530,
55700030230, 00378092393,
00228315603, 42858083940,
00093360340, 00093365940,
00093365921, 00093360321,
55700057904, 00093365640,
00093360021, 00093360040,
00093365621, 42858075040,
42858035340, 55700030330,
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00378092493, 00054017713,
42858050203, 35356055630,
62756046083, 43063075306,
43063066706, 50383093093,
00093537956, 68308020830,
00228315303, 62991158306,
51927101200, 49452825301,
63275992205, 63370090510,
38779088805, 63275992204,
63275992202, 51552076509,
51552076502, 49452825302,
63275992207, 63275992203,
38779088801, 51552076506,
38779088809, 62991158301,
49452825303, 62991158304,
63275992201, 38779088806,
38779088800, 63370090509,
63370090506, 63370090515,
62991158302, 62991158303,
51552076501, 62991158308,
62991158307, 38779088803,
12496127802, 49999063830,
12496131002, 49999063930,
63874117303, 12496121201,
12496121203, 12496120201,
12496120203, 63874108503,
63629402801, 12496128302,
68258299903, 52959074930,
49999039515, 68071151003,
49999039530, 49999039507,
16590066630, 54868575000,
12496120403, 12496120401,
55700014730, 12496120803,
12496120801, 54569639900,
55045378403, 68071138003,
12496130602, 54569573902,
54868570700, 52959030430,
63629403402, 63874108403,
54569573901, 63629403401,
63629403403, 54868570703,
54868570704, 43063018430,
66336001630, 54868570702,
35356000407, 35356000430,
43063018407, 54868570701,
54569573900, 59385001230,
59385001201, 59385001430,
59385001401, 59385001601,
59385001630, 52440010014,
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58284010014, 12496010001,
12496010005, 12496010002,
12496030002, 12496030005,
12496030001, 54123090730,
54123091430, 54123011430,
54123092930, 54123095730,
54123098630, 00185003930,
68115068030, 51224020630,
68084029111, 68094085362,
54868557400, 00555090201,
16729008101, 16729008110,
52152010502, 00406117001,
42291063230, 43063059115,
47335032683, 00185003901,
00555090202, 51224020650,
52152010504, 52152010530,
00406117003, 50436010501,
47335032688, 68084029121,
10695004310, 10695004305,
62991124303, 62991124302,
62991124304, 60966024403,
62991124301, 60966014404,
60966034402, 38779088708,
51927275300, 62991312501,
62991312503, 62991312504,
52372075103, 51552073701,
63275990103, 55812033302,
63370015810, 49452483505,
58597840701, 58597840704,
55812033301, 62991312502,
00395808335, 51552073704,
58597840702, 63275990101,
63275990102, 63275990104,
63275990105, 63370015825,
38779088703, 38779088706,
58597840706, 51927360200,
63370015815, 52372075101,
52372075102, 00395808362,
49452483502, 63370015835,
38779088704, 38779088705,
49452483503, 00395808319,
51552073702, 51927437700,
55812033303, 49452483501,
51927354800, 65757030202,
65757030001, 63459030042,
51285027501, 51285027502
Other drug
use disorder

292.x, 304.1x,
304.2x, 304.4x,

F13.1-F13.29,
F14.1-F14.29,
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(non-opioid
substance use
disorder)

304.5x, 304.6x,
F15.1-F15.29,
304.7x, 304.8x,
F16.1-F16.29,
304.9x, 305.3x,
F18.1-F18.29,
305.4x, 305.6x,
F19.1-F19.29
305.7x, 305.9x
ICD-9, International Classification of Disease, Ninth Revison; ICD-10, International
Classification of Disease, Tenth Revision; HCPCS, Healthcare Common Procedure Coding
System; NDC, National Drug Code
Notes: Non-opioid substance use disorders exclude codes 304.7x.
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Appendix B
Steps and codes for determining numerator and denominator for the clinical performance
measures for contraceptive care

Source: Department of Health and Human Services’ Office of Population Affairs
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Diagnosis or
procedure
Infecund for
noncontraceptive
reasons (i.e.,
hysterectomy,
oophorectomy,
or menopause)

Pregnancy

ICD-9
V49.81, V88.01,
256, 256.1,
256.2, 256.31,
256.39, 256.8,
627.1, 627.2,
627.3, 627.8,
627.9

ICD-10
E89.40, E89.41,
E28.310,
E28.319, E28.39,
N95.0, N95.1,
N95.2, Z78.0,
Z90.710,
Z90.722

V22.x, V23.x,
V23.xx, V24.x,
V27.x, V28.x,
V28.xx, V61.6,
V61.7, V72.42,
V91.xx, 630-

O00-O9A, Z33.x,
Z34.x, Z37.x,
Z39.x
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HCPCS
58150,
58152,
58180,
58200,
58210,
58240,
58260,
58262,
58263,
58267,
58270,
58275,
58280,
58285,
58290,
58291,
58292,
58293,
58294,
58541,
58542,
58543,
58544,
58548,
58552,
58554,
58570,
58571,
58572,
58573,
58943,
58950,
58951,
58952,
58953,
58954,
58956,
58957,
58958,
58960
59812,
59820,
59821,
59830,
59120,
59121,

NDC

679.14, 72.073.99, 74.074.20, 74.40,
74.99

Miscarriage,
ectopic
pregnancy,
stillbirth, or
induced
abortion

630-637.92,
639.0-639.9,
656.40, V27.1,
V27.4, V27.7
656.41, 656.43

O00-O08, O36.4,
Z33.2, Z37.1,
Z37.4, Z37.7

Delivery
ending in a
live birth

640.x1, 641.x1,
642.x1, 642.x2,
643.x1, 644.21,

10D00Z0,
10D00Z1,
10D00Z2,
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59130,
59135,
59136,
59140,
59840,
59841,
59850,
59851,
59852,
59855,
59856,
59857,
59400,
59409,
59410,
59412,
59425,
59426,
59510,
59514,
59515,
59610,
59612,
59614,
59618,
59620,
59622
59812,
59820,
59821,
59830,
59120,
59121,
59130,
59135,
59136,
59140
59840,
59841,
59850,
59851,
59852,
59855,
59856,
59857
59400,
59409,
59410,

Sterilization

Intrauterine
Device

645.x1, 646.x1,
646.x2, 647.x1,
647.x2, 648.x1,
648.x2, 649.x1,
649.x2, 650,
651.x1, 652.x1,
653.x1, 654.x1,
654.x2, 655.x1,
656.01, 656.11,
656.21, 656.31,
656.51, 656.61,
656.71, 656.81,
656.91, 657.01,
658.x1, 659.x1,
660.x1, 661.x1,
662.x1, 663.x1,
664.x1, 665.x1,
665.x2, 666.x2,
667.x2, 668.x1,
668.x2, 669.x1,
669.x2, 670.02,
671.x1, 671.x2,
672.02, 673.x1,
673.x2, 674.x1,
674.x2, 675.x1,
675.x2, 676.x1,
676.x2, 678.x1,
679.x1, 679.x2,
V27.0, V27.2,
V27.3, V27.5,
V27.6, 670.12,
670.22, 670.32,
670.82, 72.073.99, 74.074.20, 74.40,
74.99
V25.2, V26.51,
66.2

10D07Z3,
10D07Z4,
10D07Z5,
10D07Z6,
10D07Z7,
10D07Z8,
10E0XZZ

59510,
59514,
59515,
59610,
59612,
59614,
59618,
59620,
59622

Z30.2, Z98.51,
0U574ZZ,
0U578ZZ,
0UL74CZ,
0UL74DZ,
0UL74ZZ,
0UL78DZ,
0UL78ZZ

58600,
58605,
58615,
58611,
58670,
58671,
58565,
A4264

V25.11, V25.13,
V25.42, V45.51,

Z30.014,
Z30.430,

58300,
J7300,
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00023585801, 50419042101,
50419042201, 50419042208,

(IUD/IUS)

996.32, 69.7

Hormonal
Implant

V25.5, V25.43,
V45.52

Injectable(1month/3month)

Oral
contraceptive
pills

V25.01, V25.41

Z30.433,
Z30.431, Z97.5,
T83.31XA,
T83.31XD,
T83.31XS,
T83.32XA,
T83.32XD,
T83.32XS,
T83.39XA,
T83.39XD,
T83.39XS,
0UH97HZ,
0UH98HZ,
0UHC7HZ,
0UHC8HZ
Z30.017, Z30.46

J7301,
J7302,
S4989,
Q0090,
S4981

50419042271,
50419042301,50419042308,
50419042401,50419042408,
50419042471, 51285020401,
51285020402, 52544003554

00052027201, 00052027401,
00052027480, 00052433001

Z30.013, Z30.42

11981,
11983,
J7306,
J7307
J1050

Z30.011, Z30.41

S4993
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00009062601, 00009074630,
00009074635, 00009470901,
00009470913, 00009737604,
00009737607, 00009737611,
00247210801, 00703680101,
00703680104, 00703681121,
23490585401, 52125064001,
52125091501, 54569370100,
54569490400, 54569552700,
54569561600, 54569621900,
54868334801, 54868361300,
54868410000, 54868410001,
54868525700, 55045350501,
59762453701, 59762453702,
59762453801, 59762453802,
59762453809, 68788923301
00008111720, 00008111730,
00008251402, 00008253505,
00008253601,00008253605,
00052026106, 00052026108,
00052028306, 00052028308,
00062125100, 00062125115,
00062125120, 00062133220,
00062141116, 00062141123,
00062171400,00062171415,
00062176100, 00062176115,
00062178100, 00062178115,
00062179600, 00062179615,
00062190120, 00062190320,

00062190700, 00062190715,
00062191000, 00062191015,
00093214062, 00093209028,
00093209058, 00093313482,
00093313491, 00093532862,
00093542328, 00093542358,
00093566128, 00093566158,
00093614882, 00093614891,
00247052028, 00247069028,
00247069128, 00247069228,
00247139828, 00247151328,
00247151628, 00247151728,
00247176404, 00247176421,
00247176521, 00247198621,
00247198628, 00247200828,
00247201004, 00247201008,
00247201028, 00247201228,
00247201328, 00247214728,
00247216928, 00247217028,
00247223028, 00247223528,
00247226028, 00247226828,
00378728153,00378655053,
00378655056,00378727253,
00378727753, 00378728098,
00378728398, 00378728590,
00378728756, 00378729253,
00378729656, 00378729853,
00378730053, 00378730153,
00378730853, 00430000531,
00430001005, 00430042014,
00430042060, 00430042095,
00430048214, 00430048295,
00430053014, 00430053060,
00430053095, 00430053550,
00430054050, 00430057014,
00430057045, 00430057060,
00430058014, 00430058045,
00430058114, 00430058514,
00430058545, 00555034458,
00555071558, 00555900867,
00555900942, 00555901058,
00555901258, 00555901467,
00555901658, 00555901858,
00555902058, 00555902542,
00555902557, 00555902658,
00555902742, 00555902757,
00555902858, 00555903270,
00555903458, 00555904358,
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00555904558,00555904758,
00555904958, 00555905058,
00555905158, 00555905167,
00555906458, 00555906467,
00555906558, 00555906658,
00555906667,00555912366,
00555913167, 00555913179,
00603359017, 00603359049,
00603751217, 00603751249,
00603752117, 00603752149,
00603752517,00603752549,
00603754017, 00603754049,
00603760615,00603760648,
00603760715,00603760748,
00603760817, 00603760917,
00603761017, 00603761049,
00603762517, 00603762549,
00603763417, 00603763449,
00603764017, 00603764217,
00603766317, 00603766517,
00781405815,00781406015,
00781406215,00781407515,
00781410352, 00781557515,
00781558307, 00781558315,
00781558336, 00781558436,
00781558491, 00781565615,
00781565815, 16714033003,
16714034001, 16714034002,
16714034003,16714034004,
16714034601,16714034602,
16714034603, 16714034604,
16714034701, 16714034702,
16714034703, 16714034704,
16714034801, 16714034802,
16714034803, 16714034804,
16714035901, 16714035902,
16714035904,16714036001,
16714036002, 16714036003,
16714036004, 16714036301,
16714036302, 16714036303,
16714036304, 16714036501,
16714036502, 16714036503,
16714036504, 16714036603,
16714037001, 16714037002,
16714037003, 16714037004,
16714040701, 16714040702,
16714040703, 16714040704,
16714041601, 16714041602,
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16714041603, 16714041604,
16714044001, 16714044002,
16714044003, 16714044004,
16714044101, 16714044102,
16714044103, 16714044104,
16714046401,16714046402,
16714046403, 16714046404,
21695040701, 21695068528,
21695076928, 21695077001,
21695077028, 21695085501,
21695085701, 21695099528,
23490765301, 23490767001,
23490769901, 24090080184,
24090096184,34908062051,
34908062053, 34908062056,
35356001468, 35356001568,
35356002168, 35356025528,
35356037028, 50090015901,
50102010048, 50102012048,
50102012803, 50102013048,
50102015403, 50419040201,
50419040203, 50419040300,
50419040303, 50419040370,
50419040375, 50419040503,
50419040700, 50419040701,
50419040703, 50419040770,
50419040775, 50419041112,
50419041128, 50419043306,
50419043312, 50452025115,
50458017115, 50458017615,
50458017815, 50458017820,
50458019115, 50458019120,
50458019411, 50458019416,
50458019423, 50458019615,
50458019715, 50458019720,
50458025115, 51285005866,
51285007997, 51285008070,
51285008198, 51285008297,
51285008370, 51285008498,
51285008787, 51285009158,
51285009287,51285011458,
51285012058, 51285012570,
51285012698, 51285012797,
51285012870, 51285012998,
51285013197, 51285043165,
51285054628, 51660012786,
51660057286, 52544005431,
52544006431,52544008728,
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52544014331, 52544016528,
52544016731, 52544017572,
52544020431, 52544021028,
52544021928, 52544022829,
52544022891, 52544023328,
52544023528, 52544023531,
52544024531, 52544024728,
52544024828, 52544024928,
52544025428, 52544025928,
52544025988, 52544026528,
52544026531, 52544026829,
52544026884, 52544027428,
52544027431, 52544027621,
52544027928, 52544029021,
52544029128, 52544029231,
52544029241, 52544029528,
52544038328, 52544038331,
52544038428, 52544038431,
52544055028, 52544055031,
52544055228,52544055231,
52544055428, 52544055431,
52544062928, 52544063028,
52544063128, 52544084728,
52544084731, 52544084828,
52544089228, 52544093628,
52544094028, 52544094928,
52544095021, 52544095121,
52544095328, 52544095428,
52544095931, 52544096691,
52544096728, 52544098131,
52544098228, 52544098231,
54569067900, 54569068500,
54569068501, 54569068900,
54569068901, 54569143900,
54569384400, 54569422200,
54569422201, 54569426900,
54569427301, 54569481700,
54569487800, 54569487801,
54569489000, 54569498400,
54569499700, 54569499800,
54569516100, 54569534900,
54569549300, 54569549302,
54569579600, 54569579700,
54569579800, 54569581600,
54569582600, 54569603200,
54569612800, 54569614400,
54569627200, 54569628000,
54569628100, 54868042800,
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54868044300, 54868050200,
54868050700, 54868050801,
54868050901, 54868051600,
54868151200, 54868156400,
54868231600, 54868260600,
54868270100, 54868377200,
54868386300, 54868394800,
54868409300, 54868423900,
54868436900, 54868404500,
54868424000, 54868453800,
54868459000, 54868460700,
54868473000, 54868473100,
54868474200, 54868474400,
54868474500, 54868475400,
54868477600, 54868477800,
54868481400, 54868482800,
54868485000, 54868485100,
54868486000, 54868491100,
54868502800, 54868503100,
54868528600, 54868532600,
54868535600, 54868582600,
54868582800, 54868592200,
54868593500, 54868594200,
54868604400, 54868610000,
54868616100, 54868616200,
54868621000, 54868627200,
54868627300, 54868627400,
54868627500, 54868627600,
55045348506, 55045349701,
55045349801, 55045378106,
55045378206,55289024708,
55289088704, 55887005228,
55887028628, 57297087713,
58016474701, 58016482701,
61786038206, 61786038506,
63187005428, 63187045828,
66116043628, 66116047028,
66993061128, 66993061528,
68180083713,68180084313,
68180084413, 68180084613,
68180084813, 68180085413,
68180085713, 68180086413,
68180086513, 68180086613,
68180087611, 68180087613,
68180088013, 68180089213,
68180089713, 68180089813,
68180089913, 68180090213,
68180090313, 68258500502,
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68462013281, 68462030329,
68462030529, 68462030929,
68462031629, 68462031829,
68462038829, 68462039429,
68462055629, 68462056529,
68462063729, 68462064693,
68462065629, 68462065690,
68462065729, 68462065790,
68462067295, 68462071929,
68462072029, 76388028301,
76388028306, 76413010428,
76413010528, 76413011128,
76413011628, 76413011828,
76413012128, 76413012828,
76413013028, 00378728053,
00378728353, 00378728753,
00378729653, 00430053750,
16714007304, 16714035903,
16714036704, 16714040402,
16714040404, 16714040501,
16714040504, 16714040601,
16714040604, 16714040803,
16714041304, 50419040903,
65162031684, 65162034784,
68180087513, 68180087711,
68180087713, 68180088213,
68180088613, 68180089211,
68180089313, 75854060101,
63187074828, 51862010206,
00093542362, 51862003603,
51862003601, 51862026006,
00378730653, 51862002801,
51862054506, 69238153106,
51862002806, 51862009706,
51862031801, 51862031803,
51862000706, 68462013279,
51862027906, 51862027901,
51862056406, 51862056401,
69238155106, 52544029841,
52544029831, 00378729753,
68180087311, 68180087313,
00023586228, 00023586230,
51862001201, 51862001206,
51862029201, 51862029206,
51862007206, 51862023803,
51862051006, 51862047006,
51862047106, 63187075428,
68180083811, 68180083813,
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Patch

Z30,016, Z30.45

J7304

Vaginal ring

Z30.015, Z30.44

J7303

Diaphragm

Discontinue
Intrauterine
device (IUD)
Discontinue

57170,
A4261,
A4266

V25.12, 97.71

Z30.432,
0UPD7HZ,
0UPD8HZ

58301
11976,

158

51862028403, 51862004591,
00378728490, 51862004701,
51862004791
00062192001, 00062192015,
00062192024, 50458019201,
50458019215,50458019224,
54569541300, 54868467000,
00378334053
00052027301, 00052027303,
00052027385, 54569586500,
54868483201, 55887075401,
76413013103
00027013160, 00027013180,
00062330100, 00062330200,
00062330300, 00062330400,
00062330500, 00062330600,
00062330700, 00062330800,
00062330900, 00062331000,
00062331100, 00062331200,
00062331300, 00062334100,
00062334200, 00062334300,
00062334400, 00062334500,
00062334600, 00062334700,
00062334800, 00062334900,
00062335000, 00062335100,
00062335200, 00062338100,
00062338200, 00062338300,
00062338400, 00062338500,
00062338600, 00062338700,
00062338800, 00062338900,
00062364103, 00062364300,
00234005100, 00234013100,
00234013150, 00234013155,
00234013160, 00234013165,
00234013170, 00234013175,
00234013180, 00234013185,
00234013190, 00234013195,
00234013600, 00234013660,
00234013665, 00234013670,
00234013675, 00234013680,
00234013685, 00234013690,
00234013695, 00396401065,
00396401070, 00396401075,
00396401080

implant
11982
ICD-9, International Classification of Disease, Ninth Revison; ICD-10, International
Classification of Disease, Tenth Revision; HCPCS, Healthcare Common Procedure Coding
System; NDC, National Drug Code
Notes: Codes listed above were used to calculate contraceptive care measures for years 20002016. Codes used to calculate measures for 2017 deviated slightly from the codes listed above.
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Appendix C
Classification of rurality using United States Department of Agriculture 2003 and 2013
Urban Influence Codes
Metropolitan counties
1 In large metro area of 1 million or more residents
2 In small metro area of less than 1 million residents
Nonmetropolitan counties
3 Micropolitan area adjacent to large metro area
4 Noncore adjacent to large metro area
5 Micropolitan area adjacent to small metro area
Noncore adjacent to small metro area and contains a town of at least
6 2,500 residents
Noncore adjacent to small metro area and does not contain a town of
7 at least 2,500 residents
8 Micropolitan area not adjacent to a metro area
Noncore adjacent to micro area and contains a town of at least 2,500
9 residents
Noncore adjacent to micro area and does not contain a town of at
10 least 2,500 residents
Noncore not adjacent to metro or micro area and contains a town of at
11 least 2,500 residents
Noncore not adjacent to metro or micro area and does not contain a
12 town of at least 2,500 residents
Notes: Metropolitan was classified as urban and non-metropolitan was classified as rural.

County of residence
Abbeville County
Aiken County
Allendale County
Anderson County
Bamberg County
Barnwell County
Beaufort County
Berkeley County
Calhoun County
Charleston County
Cherokee County
Chester County
Chesterfield County
Clarendon County

2003
UIC
6
2
6
2
9
6
8
2
2
2
5
3
4
6

2003
classification
Rural
Urban
Rural
Urban
Rural
Rural
Rural
Urban
Urban
Urban
Rural
Rural
Rural
Rural
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2013
UIC
5
2
6
2
9
6
2
2
2
2
5
1
4
6

2013
classification
Rural
Urban
Rural
Urban
Rural
Rural
Urban
Urban
Urban
Urban
Rural
Urban
Rural
Rural

Colleton County
Darlington County
Dillon County
Dorchester County
Edgefield County
Fairfield County
Florence County
Georgetown County
Greenville County
Greenwood County
Hampton County
Horry County
Jasper County
Kershaw County
Lancaster County
Laurens County
Lee County
Lexington County
McCormick County
Marion County
Marlboro County
Newberry County
Oconee County
Orangeburg County
Pickens County
Richland County
Saluda County
Spartanburg County
Sumter County
Union County
Williamsburg County
York County

5
2
5
2
2
2
2
5
2
5
6
2
5
2
3
2
6
2
7
6
5
5
5
5
2
2
2
2
2
5
6
1

Rural
Urban
Rural
Urban
Urban
Urban
Urban
Rural
Urban
Rural
Rural
Urban
Rural
Urban
Rural
Urban
Rural
Urban
Rural
Rural
Rural
Rural
Rural
Rural
Urban
Urban
Urban
Urban
Urban
Rural
Rural
Urban

6
2
6
2
2
2
2
5
2
5
6
2
2
2
1
2
6
2
6
6
5
5
5
5
2
2
2
2
2
2
6
1

Rural
Urban
Rural
Urban
Urban
Urban
Urban
Rural
Urban
Rural
Rural
Urban
Urban
Urban
Urban
Urban
Rural
Urban
Rural
Rural
Rural
Rural
Rural
Rural
Urban
Urban
Urban
Urban
Urban
Urban
Rural
Urban

UIC, Urban Influence Code
Notes: Classification of rurality for years 2000-2009 was based on 2003 Urban Influence Codes.
Classification of rurality for years 2010-2017 was based on 2013 Urban Influence Codes.
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Appendix D
Method and codes used to identify live birth deliveries in South Carolina Medicaid
claims
Diagnosis or
procedure
Delivery codes

Miscarriage, ectopic
pregnancy, stillbirth,
or induced abortion
(excluded)
Multiple pregnancy
(excluded)

DRG or MS-DRG
370-375, 765-768,
774-775

ICD-9
V27.xx, 650,
72.0-72.9, 73.22,
73.59, 73.6, 74.0,
74.1, 74.2, 74.4, 74.99
630-637.92, 639.0639.9, 656.40, V27.1,
656.41, 656.43

ICD-10
Z37.xx, O80.xx,
10D00Z0, 10D00Z1,
10D0021, 10D07Z3,
10D07Z4, 10D07Z5,
10D07Z6, 10D07Z7,
10D07Z8, 10E0XZZ
O00-O08, O36.4,
Z33.2, Z37.1

651.0-651.93, V27.2- O30.0-O30.93, Z37.2V27.7, V31.0-V37.2,
Z37.7, Z38.3- Z38.8
V91.0-V91.99
DRG, Diagnosis Related Group; MS-DRG, Medicare Severity-Diagnosis Related Group; ICD-9,
International Classification of Disease, Ninth Revision; ICD-10, International Classification of
Disease, Tenth Revision
Notes: A hierarchical process in the order listed above was used to identify deliveries.
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Appendix E
Diagnosis and procedure codes used to identify chronic conditions listed in the United
States Medical Eligibility Criteria for Contraceptive Use and mental health comorbidities
Diagnosis or
procedure
Mental health
diagnosis (excluding
substance use, abuse
and dependence
codes)
Breast cancer

ICD-9
290-319

ICD-10
F10-F99

174.x, 198.81,
233.0

D05, C50.0, C50.01x, C50.11x,
C50.21x, C50.31x, C50.41x,
C50.51x, C50.61x, C50.81x,
C50.91x, C79.81
Z68.41, Z68.42, Z68.43, Z68.44,
Z68.45, 0DV64CZ, 0D164Z9,
0D164ZA, 0D160ZA, 0D160ZB,
0DQ60ZZ, 0DB60ZZ, 0DB80ZZ,
0D190Z9
I26, I80.1-I82

Malabsorptive
bariatric surgery

43.7, 43.89,
44.38, 44.39,
44.5, 45.51,
45.91

Venous
thromboembolism
Valvular heart disease

415.x, 451.x,
453.x
394.0-397.0,
424.x, V43.3
710.0

Systematic lupus
erythematosus
Liver cancer
Severe liver cirrhosis
Ischemic heart
disease
Chronic hypertension
Stroke
Migraine with aura
Diabetes
Peripartum
cardiomyopathy
Malignant gestational
trophoblastic disease
Epilepsy
Ovarian cancer

155.x, 197.7,
230.8, 235.3
571.2, 571.5
410.0x-414.9,
429.2
362.11, 405.0x405.99
430-438.9
346.0x, 346.3x,
346.5x, 346.6x,

I05-I08, I34-I37, Z95.2, Z95.4
M32.10, M32.9
C22, D01.5, D37.6
K70.30, K74.0, K74.6x
I20-I25
H35.03x, I10-I15, I67.4, N26.2

250.0x-250.9x
674.5x

I60-I69
G43.10x, G423.11x, G43.40x,
G43.41x, G43.50x, G43.51x,
G43.60x, G43.61x
E10-E14
O90.3

236.1, 181

D39.2, C58

345.0x-345.5x,
345.7x-345.9x
183.x, 198.6

G40
C56, C57, C79.6x
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HCPCS

43633, 43644,
43645, 43845,
43846, 43847,

Endometrial cancer
Thrombogenic
mutations
Tuberculosis
Sickle cell disease
Schistosomiasis with
fibrosis of liver
Solid organ
transplantation

182.0, 182.1,
182.8, 233.2
289.81

C54, D07.0

010-018
282.6x
120.x

A15-A19
D57.0x-D57.21x, D57.80-D57.81x
B65

D68.5x

996.81, 996.82,
996.83, 996.84,
996.86, V42.0,
V42.1, V42.6,
V42.7, 33.50,
33.51, 33.52,
37.51, 50.51,
50.59, 52.80,
55.61, 55.69

Z93.4, Z94.0, Z94.1, Z94.2, Z94.3, 32851, 32852,
Z94.83, T86.1x-T86.4x, T86.81x,
32853, 32854,
02YA0Z0, 02YA0Z1, 02YA0Z2,
32855, 32856,
0FY00Z0, 0FY00Z1, 0FY00Z2,
33927, 33928,
0FYG0Z0, 0FYG0Z1, 0FYG0Z2,
33929, 33933,
0BYK0Z0, 0BYK0Z1, 0BYK0Z2,
33935, 33944,
0BYL0Z0, 0BYL0Z1, 0BYL0Z2,
33945, 33975,
0BYC0Z0, 0BYC0Z1, 0BYC0Z2,
33976, 33977,
0BYD0Z0, 0BYD0Z1, 0BYD0Z2,
33978, 33979,
0BYF0Z0, 0BYF0Z1, 0BYF0Z2,
44715, 44720,
0BYG0Z0, 0BYG0Z1, 0BYG0Z2,
44721, 47125,
0BYH0Z0, 0BYH0Z1, 0BYH0Z2,
47130, 47133,
0BYJ0Z0, 0BYJ0Z1, 0BYJ0Z2,
47135, 47143,
0BYK0Z0, 0BYK0Z1, 0BYK0Z2,
47144, 47145,
0BYL0Z0, 0BYL0Z1, 0BYL0Z2,
47146, 47147,
0BYM0Z0, 0BYM0Z1, 0BYM0Z2, 48160, 48550,
0TS00ZZ, 0TS10ZZ, 0TY00Z0,
48551, 48552,
0TY00Z1, 0TY00Z2, 0TY10Z0,
48554, 48556
0TY10Z1, 0TY10Z2
ICD-9, International Classification of Disease, Ninth Revision; ICD-10, International
Classification of Disease, Tenth Revision; HCPCS, Healthcare Common Procedure Coding
System
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Appendix F
Moderator guide used for the interviews
Hello, thank you for joining me today. My name is Betsy, and I am a research assistant at
Clemson University. How are you today?
Thank you for your time and your interest in this study. Before we begin, I would like to
make sure that you qualify for the study.
Are you in a role where you provide contraceptive counseling to women with substance
use disorder (SUDs)?
Exclusion criteria:
Does not provide contraceptive counseling to women with SUDs as part of his/her
duties
Non-provider staff (i.e. other non-provider staff in the office setting, such as
administrative staff)
Non-English speaking providers
AFTER PROVIDER ANSWERS: Great, then before we start, I wanted to tell you a little
bit about the study. I am a PhD student at Clemson University. For my dissertation
project, I am trying to learn about how healthcare practioners with prescriptive authority
are providing contraceptive counseling to women with substance use disorders (SUD).
Today, I am specifically interested in how you provide counseling to women with drug
and alcohol use disorders, not tobacco use disorders.
Our discussion will last no more than 30 minutes, to be respectful of your time, but there
is no time limit. There are no right or wrong answers in this discussion, so please feel
free to share your practices. We will not retain any personal identifying information for
this study. Do you have any questions for me?
Please feel free to stop me and ask questions at any time during our discussion. Also,
since we will be speaking for a while today, and it’s hard for me to remember
everything, would it be okay if I recorded our conversation?
Thank you! We will transcribe your responses, ensuring confidentiality, and digital
recordings will be destroyed after the files are transcribed.
ICEBREAKER
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Question 1: How long have you been providing contraceptive counseling to women with
SUDs?
Question 2: How do you define contraceptive counseling at your practice?
LEAD IN: Great, the remainder of my questions today will be about your experience
providing contraceptive counseling specifically to women with drug use disorders.
INTERVIEW QUESTIONS
1) Tell me about your contraceptive counseling discussions with your patients who have
SUDs.
Probes: ideal time period, particular trimester or visit, how often, who participates
2) Tell me about contraception information that you share with patients who have SUDs.
Probes: safety, efficacy, side effects, correct use, address concerns, correct
misconceptions, dual STI counseling, format
3) Help me understand what contraceptive counseling approaches you have found most
effective for women with SUDs.
Probes: dialoguing, decision-making, relationship, partners, follow-up
4) As I'm listening to you, I am wondering if you can help me understand how
counseling may differ for someone with an active SUD as compared to someone in
recovery.
Probes: substance of choice. information, approaches, time period of counseling
5) I’m also wondering, since I'm not a clinician like you, if you can help me understand
how counseling someone without a SUD might compare to counseling someone with
one.
Probes: information, approaches, time period of counseling
6) As a provider, help me understand what contraceptive counseling resources you
would like in order to support your efforts serving women with SUDs.

166

Probes: More CEU opportunities, more time, more mid-level staff to help with education,
support groups for patients, funding.
DEMOGRAPHICS
Before we end, would you mind providing some quick demographic information. I am
asking these questions of everyone that I interview. Please feel free to decline to answer
any of these questions.
What is your gender:
Male or Female
What is your race/ethnicity:
non-Hispanic white; non-Hispanic black; Hispanic or Latino; Asian; American
Indian; Other
What is your age group:
Between 25-34; 35-44; 45-54; 55-64
What is your specialty?
Open ended
What population do you serve?
Open ended
About how many patients do you see in your practice?
Open-ended
Approximately how many of your patients have a diagnosed SUD?
Open-ended
CLOSING
Do you have anything else you would like to add? Do you have any questions for me?
Thank you very much for your time today.
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